Treating heart disease by inhibiting PP2A anchoring

Abstract

The present invention provides a method for treating heart failure with reduced ejection fraction by administering to a patient at risk for such a disorder a pharmaceutically effective amount of a composition that inhibits anchoring of PP2A to mAKAPβ, preferably in the form of a viral-based gene therapy vector encoding a fragment of mAKAPβ to which PP2A binds.

Description

[Technical field]

[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to U.S. Provisional Patent Application No. 62 / 848,156, filed May 15, 2019, which is incorporated herein by reference in its entirety, which is U.S. Provisional Patent Application No. 14 / 821,082, filed August 7, 2015, now U.S. Patent No. 9,937,228, issued April 10, 2018, and U.S. Patent Application No. 20 / 02 / 2009, which is incorporated herein by reference in its entirety. No. 14 / 213,583, now U.S. Patent No. 9,132,174, issued September 15, 2015, U.S. Patent Application No. 16 / 028,004, filed July 5, 2018, U.S. Provisional Patent Application No. 61 / 798,268, filed March 15, 2013, and U.S. Provisional Patent Application No. 62 / 529,224, filed July 6, 2017, are incorporated by reference in their entireties.

[0002] [Statement regarding government support] This invention was made with Government support under Contract Nos. RO1 HL 075398 and HL126825 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]

[0003] Upon chronic stress, the heart's primary compensatory mechanism is myocyte hypertrophy, a nonmitotic increase in contractile cell volume (Hill and Olson 2008). Adult mammalian myocytes are roughly cylindrical and can grow in either width or length. Because myocytes contribute the majority of the cardiac myocardial mass (Jugdutt 2003), concentric and eccentric hypertrophy of myocytes results in ventricular wall thickening and ventricular dilation, respectively. Theoretically, widthwise "concentric" myocyte growth, which engages the parallel structure of the sarcomere, reduces ventricular wall stress (Law of LaPlace), while lengthwise "eccentric" myocyte growth, which engages the continuous structure of the sarcomere, can accommodate larger ventricular volumes without stretching individual sarcomeres beyond their optimal length for contraction (length-tension relationship) (Grossman, Jones, and McLaurin 1975). While the left ventricle hypertrophies relatively symmetrically following physiological stresses such as pregnancy or exercise training, concentric ventricular hypertrophy is the primary early response to increased systolic wall stress present in pressure-overload disorders such as hypertension or aortic stenosis. Eccentric ventricular hypertrophy predominates in conditions of volume overload, such as those occurring after myocardial infarction, and in the transition from concentric hypertrophy to a dilated heart in heart failure with reduced ejection fraction (HFrEF) in certain forms of cardiovascular disease, including disorders characterized primarily by pressure overload. Eccentric and concentric hypertrophy are also present in hereditary hypertrophy and dilated cardiomyopathy, respectively.

[0004] At the cellular level, cardiomyocyte hypertrophy occurs as a result of increased protein synthesis and sarcomere size and organization within individual myocytes. For a fuller discussion of cardiac remodeling and hypertrophy, see Kehat (2010) and Hill (2008), each of which is incorporated herein by reference in its entirety. The prevailing view is that cardiac hypertrophy plays a major role in the development of heart failure. Conventional methods of treating heart failure include afterload reduction, inhibition of beta-adrenergic receptors (β-ARs), and the use of mechanical support devices in affected patients. However, this technology requires additional mechanisms to prevent or treat pathological cardiac hypertrophy.

[0005] Studies suggest that mechanisms inducing "compensatory" concentric hypertrophy early in pressure overload-related heart disease predispose the heart to later systolic dysfunction and eventual failure (Schiattarella and Hill 2015). In this regard, results have shown that targeting the RSK3-mAKAPβ complex can attenuate pressure overload-induced cardiac remodeling and prevent heart failure (Kritzer et al. 2014; Li, Kritzer, et al. 2013). Thus, inhibition of signaling pathways that induce remodeling, including concentric hypertrophy, may be desirable early in pressure overload disease. However, the question remains whether efforts to promote concentric hypertrophy and maintain signals that oppose eccentric hypertrophy could preserve cardiac volume and evoked contractility when the heart is at a stage in the disease process characterized by eccentric growth and ventricular enlargement that leads to HFrEF, even in the later stages of pressure overload-related disease, or in the progression of volume overload-related disease. Furthermore, it is unknown whether enhancing concentric myocyte hypertrophy and / or inhibiting eccentric myocyte hypertrophy in familial dilated cardiomyopathy may be beneficial.

[0006] AKAP and Cardiac Remodeling Ventricular myocyte hypertrophy is the primary compensatory mechanism that relieves ventricular wall tension when the myocardium is stressed due to myocardial infarction, hypertension, and congenital heart disease, or neurohumoral activation. It is associated with non-mitotic growth of cardiomyocytes, myofibrillar organization, and upregulation of a specific subset of "fetal" genes that are normally expressed during the embryonic stage (Frey 2004, Hill 2008). Synchronized abnormal cardiac contractions, Ca 2+Handling, and myocardial energetics are associated with maladaptive changes that include interstitial fibrosis and cardiomyocyte death, as well as increasing the risk of developing heart failure and malignant arrhythmias (Cappola 2008, Hill 2008). Both adaptations contribute to both systolic and diastolic dysfunction that are present in varying proportions depending on the underlying disease (Sharma and Kass 2014). Pathological remodeling of myocytes involves the regulation of mitogen-activated protein kinases (MAPK), cyclic nucleotides, Ca 2+ , hypoxia, and phosphoinositide-dependent signaling pathways (Heineke and Molkentin 2006).

[0007] In the United States, heart failure affects 6.2 million adults, with approximately 1,000,000 new cases diagnosed annually in adults, due to increased prevalence caused by risk factors such as smoking and obesity (Benjamin et al. 2019). The prevalence and incidence of heart failure are increasing, primarily due to increased life expectancy, but also due to increased prevalence of risk factors (hypertension, diabetes, dyslipidemia, and obesity) and increased survival of other types of cardiovascular disease (myocardial infarction [MI] and arrhythmias) (Heidenreich et al. 2013). First-line therapy for patients with heart failure includes angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic receptor blockers (β-blockers), which can improve survival and quality of life in such patients and reduce mortality in patients with left ventricular dysfunction (Group 1987). Subsequent or alternative therapies include aldosterone and angiotensin II receptor blockers, neprilysin inhibitors, loop and thiazide diuretics, vasodilators, and I f current blockers, as well as device-based therapies (Ponikowski et al. 2016). Nevertheless, the 5-year mortality rate for symptomatic heart failure remains approximately 50%, including a mortality rate of over 40% after MI (Heidenreich et al. 2013; Gerber et al. 2016).

[0008] Cardiac hypertrophy can be induced by a variety of neurohumoral, paracrine, and autocrine stimuli that activate several receptor families, including G protein-coupled receptors, cytokine receptors, and growth factor tyrosine kinase receptors (Brown 2006, Frey 2004). In this context, it is gradually becoming clear that A-kinase anchoring proteins (AKAPs) can assemble multiprotein complexes that integrate the hypertrophic pathways emanating from these receptors. In particular, recent studies have now identified anchoring proteins, including mAKAP, AKAP-Lbc, and D-AKAP1, that function as scaffolding proteins and play a central role in orchestrating and regulating the hypertrophic pathways activated by stress signals.

[0009] As organizers of "nodes" in intracellular signaling networks, scaffolding proteins have become of interest as potential therapeutic targets (Negro, Dodge-Kafka, and Kapiloff 2008). In cells, scaffolding proteins can organize multimolecular complexes called "signalosomes" that constitute a key mechanism responsible for specificity and efficacy in intracellular signaling (Scott and Pawson 2009). First, many signaling enzymes have broad substrate specificity. Scaffolding proteins can colocalize these pleiotropic enzymes with their individual substrates, selectively enhancing catalysis of substrates and conferring a degree of specificity that is not inherent to the enzyme's active site (Scott and Pawson 2009). Second, some signaling enzymes are low in abundance. Scaffolding proteins can colocalize rare enzymes with their substrates, kinetically favoring signaling. Third, many scaffolds are multivalent, so that scaffold binding can orchestrate the co-regulation of individual substrate effectors by multiple enzymes. Muscle A-kinase anchoring protein (mAKAP, also known as AKAP6) mediates the broad substrate specificity of protein kinase A (PKA) and Ca 2+mAKAPβ is a large scaffold expressed in cardiac and skeletal muscle cells and neurons that binds both signaling enzymes such as the calmodulin-dependent phosphatase calcineurin (CaN) and the particularly low abundance p90 ribosomal S6 kinase 3 (RSK3) (Figure 1) (Wang et al. 2015;Pare, Easlick, et al. 2005;Michel et al. 2005a;Kapiloff et al. 1999b). mAKAPβ is an alternatively spliced ​​isoform expressed in muscle cells that localizes to the outer nuclear envelope by binding the integral membrane protein nesprin-1α in cells (Pare, Easlick, et al. 2005).

[0010] Consistent with its role as a scaffolding protein for stress-related signaling molecules in cardiomyocytes, mAKAPβ deficiency in neonatal rat ventricular myocytes in vitro inhibited hypertrophy induced by α-adrenergic, β-adrenergic, endothelin-1, angiotensin II, and leucine inhibitor / gp130 receptor signaling (Zhang et al. 2011;Pare, Bauman, et al. 2005;Dodge-Kafka et al. 2005;Guo et al. 2015). In vivo, mAKAP gene targeting in mice reduced hypertrophy induced by short-term pressure overload and chronic β-adrenergic stimulation, inhibited the development of heart failure after long-term pressure overload, and conferred a survival benefit (Kritzer et al. 2014). Specifically, mAKAP fl / fl Deletion of the mAKAP gene in tamoxifen-induced, conditional knockout mice, Tg(Myh6-cre / Esr1*), reduced left ventricular hypertrophy while significantly inhibiting myocyte apoptosis and interstitial fibrosis, left atrial hypertrophy, and pulmonary edema (edema lung weight) induced by 16 weeks of aortic coarctation (Kritzer et al. 2014).

[0011] mAKAP gene targeting is also beneficial after myocardial infarction (Kapiloff, unpublished observations). Permanent ligation of the left anterior descending artery (LAD) in mice results in myocardial infarction that includes extensive myocyte death, scar formation, and subsequent left ventricular (LV) remodeling. Four weeks after LAD ligation, mAKAP conditional knockout mice preserved LV dimensions and function compared to infarcted control cohorts. mAKAP conditional knockout mice showed a marked reduction in infarct size while preserving LV ejection fraction and index atrial mass compared to controls.

[0012] Explaining mAKAP and cardiac remodeling mAKAP was originally identified in a cDNA library screen for novel cAMP-dependent protein kinase (PKA) regulatory subunit (R subunit)-binding proteins, i.e., A-kinase anchoring proteins or AKAPs (Mccartney et al. 1995). mAKAP was initially designated "AKAP100" because of the size of the protein encoded by the original cDNA fragment (Mccartney et al. 1995). We subsequently defined the full-length mRNA sequence of mAKAPα, an alternatively spliced ​​isoform of mAKAP expressed in neurons, and revealed that wild-type mAKAPα is a 255 kDA scaffold (Kapiloff et al. 1999b). The sequence of mAKAPβ, a 230-kDa alternatively spliced ​​isoform of mAKAP expressed in striated muscle cells, was later obtained and showed that mAKAP migrates from an internal initiation site corresponding to mAKAPα residue Met-245 when expressed in cardiac or skeletal muscle (Michel et al. 2005a).

[0013] mAKAPs are localized to the nuclear envelope of both neurons and cardiac and skeletal striated muscle cells, the three cell types that clearly express mAKAPs (Figure 6) (Kapiloff et al. 1999b; Pare, Easlick, et al. 2005; Michel et al. 2005a). mAKAPs are not transmembrane domain proteins, but contain three spectrin-like repeat regions (residues 772-1187) that mediate localization (Kapiloff et al. 1999b). Binding of the third spectrin repeat (residues 1074-1187) of mAKAP by the outer nuclear envelope protein nesprin-1α is necessary and sufficient for nuclear envelope localization of mAKAPs, at least in muscle cells and when expressed in heterologous cells (Pare, Easlick, et al. 2005). Nesprin-1α may also reside in the inner nuclear envelope where it can bind A-type lamins and emerin. Interestingly, mutations in lamin A / C, emerin, and nesprin-1α have been associated with Emery-Dreifuss muscular dystrophy and other forms of cardiomyopathy (Bonne et al. 1999;Fatkin et al. 1999;Muchir et al. 2000;Bione et al. 1994;Zhang et al. 2007). However, disease-causing mutations have yet to be identified in the human mAKAP gene, and knockout of mAKAPβ in mouse hearts at early development does not induce cardiomyopathy (Kritzer et al. 2014). In addition to binding nesprin-1α, mAKAPβ may also bind phospholipase Cε (PLCε) via the first spectrin repeat of mAKAP, enhancing its association with the nuclear envelope (Zhang et al. 2011). There were early reports that mAKAPβ is present in the sarcoplasmic reticulum (Mccartney et al. 1995; Marx et al. 2000; Yang et al. 1998), but these findings have been questioned due to technical issues including antibody specificity (Kapiloff, Jackson, and Airhart 2001; Kapiloff et al. 1999b).

[0014] In addition to PKA, PLCε, and nesprin-1α, mAKAPβ is involved in the regulation of adenylyl cyclase type 5 (AC5), exchange protein activated by cAMP-1 (Epac1), cAMP-specific phosphodiesterase type 4D3 (PDE4D3), MEK5 and ERK5 MAP-kinases, 3-phosphoinositide-dependent protein kinase-1 (PDK1), p90 ribosomal S6 kinase 3 (RSK3), protein kinase Cε (PKCε), protein kinase D (PKD1, PKCμ), protein phosphatases calcineurin (CaN), Aβ, and PP2A, type 2 ryanodine receptor (RyR2), sodium / calcium exchanger NCX1, ubiquitin E3-ligases involved in HIF1α regulation, and myopodin (Pare, Bauman, et al. 2005; Pare, Easlick, et al. 2005;Dodge-Kafka et al. 2005;Marx et al. 2000;Kapiloff, Jackson, and Airhart 2001;Michel et al. 2005a;Li et al. ;Wong et al. 2008;Zhang et al. 2011;Dodge-Kafka and Kapiloff 2006;Vargas et al. 2012;Faul et al. 2007;Schulze et al. 2003;Kapiloff et al. 2009;Zhang et al. 2013) are a diverse set of proteins important in muscle cell stress responses. These signaling molecules bind to mAKAPβ and co-regulate the transcription factors hypoxia-inducible factor 1α (HIF1α), myocyte enhancer factor-2 (MEF2), and nuclear factor of activated T cells (NFATc) transcription factors, as well as type II histone deacetylases (Figure 7) (Kritzer et al. 2014; Li, Vargas, et al. 2013; Li et al. 2010; Wong et al. 2008; Li et al. 2019; Dodge-Kafka et al. 2018). Some of these molecules bind directly, some indirectly, some constitutively, and some in a regulated manner.Thus, the composition of the mAKAPβ signalosome appears to correspond to the underlying myocyte state. As mAKAPβ continues to be studied, the list of binding partners is growing, supporting its postulated role as a key orchestrator of signaling pathways required for remodeling. Most of what is known about mAKAPβ is based on studies using cultured neonatal rat ventricular myocytes, in which mAKAPβ was recognized early on as required for hypertrophy induction by a variety of upstream receptors, including α- and β-adrenergic and cytokine receptors (Pare, Bauman, et al. 2005; Dodge-Kafka et al. 2005). However, the phenotype of cardiomyocyte-specific mAKAPβ conditional knockout mice has been recently described, supporting the centrality of mAKAPβ in remodeling (Kritzer et al. 2014). There are various upstream inputs, downstream effectors (outputs), and integrated circuits within the mAKAPβ signalosome that influence pathological remodeling of the heart.

[0015] mAKAPβ - Prototype A-kinase anchor protein Like most AKAPs, mAKAP contains an amphipathic helix (residues 2055-2072) that is responsible for binding PKA (Kapiloff et al. 1999b; Kritzer et al. 2012). PKA is a heterotetramer of two R subunits and two catalytic C subunits in the configuration of the CRRC. Within the holoenzyme, the N-terminal docking and dimerization domains of the PKA R subunits form an X-shaped, antiparallel four-helix bundle (Newlon et al. 1999). This bundle contains a hydrophobic groove that corresponds to the hydrophobic face of the AKAP amphipathic helix. mAKAPβ binds PKA with high affinity (K D=119 nM) and selectively binds type II PKA (containing RII subunits) (Zakhary et al. 2000). Interestingly, PKA-mAKAPβ binding increases 16-fold after autophosphorylation of RIIα (Zakhary et al. 2000), which may affect PKA-mAKAPβ binding in altered states of β-adrenergic signaling. In addition to mAKAPβ, more than a dozen other AKAPs are expressed in muscle cells, each with its own specific localization and set of binding partners (Kritzer et al. 2014). Remarkably, mAKAP is one of the rarest AKAPs in muscle cells, such that deletion of mAKAP does not even affect perinuclear PKA localization (Kapiloff, unpublished observations). Despite low levels of scaffold expression, replacement of endogenous mAKAPβ in muscle cells with a full-length mAKAPβ mutant unable to bind PKA is sufficient to inhibit induction of muscle cell hypertrophy (Pare, Bauman, et al. 2005). Thus, the mAKAPβ signalosome illustrates both that PKA signaling can be precisely compartmentalized even in discrete organelles and that the expression level of a protein or protein complex does not necessarily indicate the functional significance of that protein.

[0016] mAKAPβ is important because it binds effectors of cAMP signaling as well as enzymes responsible for cAMP synthesis and degradation (Kapiloff et al. 2009; Dodge et al. 2001). Synthesis of cAMP from ATP is catalyzed by adenylyl cyclase (AC), whereas metabolism of cAMP to 5'AMP is catalyzed by phosphodiesterases (PDEs). Differential association of AC and PDE with AKAPs contributes to compartmentalization of cAMP in cells, both for local activation of cAMP effectors and for regulation of local cAMP levels through distinct regulatory feedback and feedforward loops (Scott, Dessauer, and Tasken 2013). mAKAPs can bind both AC2 and AC5, with AC5 being identified as the relevant mAKAPβ binding partner in the heart (Kapiloff et al. 2009). The N-terminus, C1 and C2 domains of AC5 directly bind to a unique N-terminal site (residues 275-340) of mAKAPβ. AC5 activity is inhibited in cells by PKA feedback phosphorylation promoted by mAKAPβ complex formation (Kapiloff et al. 2009). This negative feedback is considered physiologically relevant for maintaining basal cAMP signaling. When AC5 linkage to mAKAPβ was inhibited by a competitive peptide containing the mAKAP AC5-binding domain, both cAMP content and size of muscle cells increased in the absence of a hypertrophic stimulus (Kapiloff et al. 2009).

[0017] mAKAP was the first AKAP shown to bind to PDEs (Dodge et al. 2001). Sites 1286-1831 within mAKAP bind to a unique N-terminal domain of PDE4D3. Phosphorylation of serine residues 13 and 54 of PDE4D3 increases binding to scaffolds and increases PDE catalytic activity, respectively (Dodge et al. 2001; Sette and Conti 1996; Carlisle Michel et al. 2004). Because increased PDE4D3 activity speeds cAMP degradation, PKA and PDE4D3 constitute a negative feedback loop that can regulate local cAMP levels and PKA activity (Dodge et al. 2001). PDE4D3 bound to mAKAP functions not only as a PDE but also as an adaptor protein that recruits the MAPKs MEK5 and ERK5, as well as the cAMP-dependent Rap1-guanine nucleotide exchange factor Epac1 to the scaffold (Dodge-Kafka et al. 2005). Activation of MEK5 and ERK5 by upstream signals results in phosphorylation of PDE4D3 at Ser-579, inhibiting PDEs and promoting cAMP accumulation and PKA activation (Dodge-Kafka et al. 2005;Hoffmann et al. 1999;Mackenzie et al. 2008). Epac1 is not as sensitive to cAMP as PKA, such that extremely high cAMP levels result in further activity of mAKAP-associated Epac1. Epac1 inhibits ERK5 activity through Rap1, thus preventing PDE4D3 inhibition by MAPK signaling and potentially resulting in maximal PDE4D3 activity due to concomitant PKA phosphorylation (Dodge-Kafka et al. 2005).As a result, Epac1, ERK5, and PDE4D3 constitute a third negative feedback loop that can suppress cAMP levels in the vicinity of the mAKAP complex against cAMP rising to very high levels.

[0018] Further complexity is provided by the binding of the serine-threonine phosphatase PP2A to the C-terminus of mAKAP (residues 2083–2319) (Dodge-Kafka et al. 2010). PP2A can inhibit PDEs in the absence of upstream stimuli by catalyzing the dephosphorylation of Ser-54 in PDE4D3. PP2A associated with the mAKAP complex contains the B56δB subunit, a PKA substrate. PKA phosphorylation enhances PP2A catalytic activity (Ahn et al. 2007), such that phosphorylation of B56δ by mAKAP-bound PKA increases PDE4D3 dephosphorylation and inhibits PDE. This presumably increases cAMP levels, forming a positive feed-forward loop to initiate cAMP signaling. Together with the negative feedback loop based on AC5 phosphorylation and PDE4D3 regulation by PKA and ERK5, it can be predicted that cAMP levels in the mAKAPβ signalosome may be tightly controlled by upstream β-adrenergic and MAPK signaling. AC5 and ERK5 upstream signaling may promote cAMP signaling, which may be initially promoted by PP2A feed-forward signaling, while PDE4D3 activation and AC5 inhibition by PKA and Epac1 negative feedback may suppress signaling. Interestingly, Rababa'h et al. showed how mAKAP proteins containing nonsynonymous polymorphisms bind PKA and PDE4D3 differently (Rababa'h et al. 2013). The possibility that cAMP signaling may be differentially regulated by crosstalk between upstream signaling pathways or by human polymorphisms makes further studies in muscle cells that show the relevance of this complex signaling network noteworthy.

[0019] mAKAPβ and MAP-kinase-RSK3 signaling Recruitment of ERK5 to the mAKAPβ complex by PDE4D3 was initially shown to be related to the local regulation of cAMP by the aforementioned feedback loop (Dodge-Kafka et al. 2005). However, ERK5 has also been recognized as an important inducer of myocyte hypertrophy, preferentially inducing longitudinal growth (eccentric hypertrophy) in cultured myocytes, but also important for concentric hypertrophy in vivo by pressure overload (aortic coarctation in mice) (Nicol et al. 2001; Kimura et al. 2010). Notably, inhibition of mAKAPβ expression in cultured myocytes by RNA interference (RNAi) inhibited eccentric growth induced by the interleukin-6-type cytokine leukemia inhibitory factor (LIF) (Dodge-Kafka et al. 2005). A possible effector of mAKAPβ-bound ERK5 was the MEF2 transcription factor, as described below. However, in both heart and brain, mAKAP binds PDK1, a kinase that can activate the MAPK effector p90RSK, together with ERK (ERK1, 2, or 5), and the MAPK effector p90RSK is also a kinase that associates with mAKAP (Ranganathan et al. 2006;Michel et al. 2005a). Importantly, binding of PDK1 to mAKAP abolished the requirement for membrane association for RSK activation (Michel et al. 2005a). Together, these data demonstrated that mAKAPβ can orchestrate RSK activation in muscle cells in response to upstream MAPK signaling.

[0020] p90RSK is a pleiotropic ERK effector that regulates many cellular processes, including cell proliferation, survival, migration, and invasion. RSK activity is increased in myocytes by most hypertrophic stimuli (Anjum and Blenis 2008; Sadoshima et al. 1995). Moreover, RSK activity was found to be increased in human cardiac tissues with end-stage dilated cardiomyopathy (Takeishi et al. 2002). RSK family members contain two catalytic domains, an N-terminal kinase domain and a C-terminal kinase domain (Anjum and Blenis 2008). The N-terminal kinase domain phosphorylates RSK substrates and is activated by sequential phosphorylation in the activation loop of the C-terminal and N-terminal kinase domains by ERK and PDK1, respectively, such that PDK1 phosphorylation of the N-terminal domain at Ser-218 indicates full activation of the enzyme. There are four ubiquitously expressed mammalian RSK family members, but only RSK3 binds mAKAPβ (Li, Kritzer, et al. 2013). A unique N-terminal domain (1-30) in RSK3 directly binds mAKAPβ residues 1694-1833, explaining the selective association of this isoform with the scaffold (Li, Kritzer, et al. 2013). Although RSK3 is less expressed in muscle cells than other RSK family members, neonatal muscle cell hypertrophy was found to be suppressed by RNAi of RSK3, inactivation of the N-terminal kinase domain of RSK3, and inhibition of RSK3 binding to mAKAP using an anchoring disruptor peptide (Li, Kritzer, et al. 2013). Importantly, RSK3 expression in vivo was required for the induction of cardiac hypertrophy by both pressure overload and catecholamine infusion, as well as heart failure (α-tropomyosin Glu180Gly) associated with a mouse model of familial hypertrophic cardiomyopathy (Li, Kritzer, et al. 2013; Passariello et al. 2013).Moreover, consistent with the reported role of ERK1 / 2 MAP-kinases in selectively inducing centripetal hypertrophy (Kehat et al. 2011), deletion of the RSK3 gene inhibited Raf1 in a mouse model of Noonan syndrome. L613V Mutation-induced concentric hypertrophy was inhibited (Passariello et al. 2016). The recognition that this particular RSK isoform is required for cardiac remodeling makes it a noteworthy candidate for therapeutic targeting.

[0021] mAKAPβ and phosphatidylinositide signaling The cAMP effector Epac1 activates Rap1 in the mAKAPβ complex, which affects ERK5 signaling (Dodge-Kafka et al. 2005). Moreover, Epac1-Rap1 activates PLCε, a phospholipase whose Ras-associated domain directly binds the first spectrin repeat-like domain of mAKAPβ (Zhang et al. 2011). PLCε, like mAKAPβ, was required for neonatal myocyte hypertrophy even when inhibited by RNAi or by depletion from mAKAPβ by expression of a competitive binding peptide. An excellent paper by the Smrcka laboratory shows that mAKAPβ-bound PLCε regulates PKCε and PKD activation through a novel phosphatidylinositol-4-phosphate (PI4P) pathway, in which PLCε selectively converts perinuclear PI4P to diacylglycerol and inositol-1,4-bisphosphate (Zhang et al. 2013). PKD1 phosphorylates type II histone deacetylases (HDAC 4 / 5 / 7 / 9) and induces their nuclear export, derepressing hypertrophic gene expression (Monovich et al. 2010; Xie and Hill 2013). Smrcka et al. found that PLCε is required for pressure overload-induced PKD activation, type II HDAC phosphorylation, and hypertrophy in vivo (Zhang et al. 2013). Later, mAKAPβ was also found to be required for PKD activation and HDAC4 phosphorylation in response to pressure overload in vivo (Kritzer et al. 2014). Notably, mAKAPβ can form a ternary complex with PKD and HDAC4. Together, these results indicate how local cAMP signaling can affect the regulation of cardiac gene expression.

[0022] Recently, it was reported that mAKAPβ scaffolds HDAC5 in cardiomyocytes, forming a signalosome that includes HDAC5, PKD, and PKA (Dodge-Kafka et al. 2018). Inhibition of mAKAPβ expression reduced HDAC5 phosphorylation by PKD and PKA in response to α- and β-adrenergic receptor stimulation, respectively. Importantly, inhibition of mAKAPβ-HDAC5 anchoring prevented α-adrenergic receptor signaling and PKD phosphorylation-induced HDAC5 nuclear export. Moreover, inhibition of mAKAPβ-PKA anchoring prevented β-adrenergic receptor-stimulated inhibition of α-adrenergic-induced HDAC5 nuclear export. Together, these data reveal that the mAKAPβ signalosome functions to bidirectionally regulate the nucleo-plasmatic localization of class IIa HDACs. Thus, the mAKAPβ scaffold functions as a node in a muscle cell regulatory network that controls both the repression and activation of pathological gene expression in health and disease, respectively.

[0023] mAKAPβ and calcium signaling mAKAPβ mediates Ca signaling in addition to cAMP, phosphoinositide, and MAP kinase signaling. 2+ The second binding partner of mAKAPβ identified is the Ca binding partner for intracellular stores. 2+ induced Ca 2+ Ryanodine receptor Ca release 2+ The RyR2 release channel is a bulk Ca release channel (RyR2) (Kapiloff, Jackson, and Airhart 2001; Marx et al. 2000). 2+RyR2 is best known for its role in excitation-contraction coupling, where RyR2 is released to induce sarcomere contraction. PKA phosphorylation enhances RyR2 currents (Valdivia et al. 1995;Dulhunty et al. 2007;Bers 2006), but the importance of PKA-catalyzed RyR2 phosphorylation to excitation-contraction coupling is largely debated (Houser 2014;Dobrev and Wehrens 2014). A portion of RyR2 that is presumably located in perinuclear dyads (Escobar et al. 2011) can be immunoprecipitated with mAKAPβ and nesprin-1α antibodies (Pare, Easlick, et al. 2005;Kapiloff, Jackson, and Airhart 2001). mAKAPβ is recognized to bring together components of the excitation-contraction coupling machinery and signaling molecules that are important in regulating nuclear events related to pathological remodeling. Thus, the mAKAPβ complex may provide a mechanism for adapting contraction to induced hypertrophy. β-Adrenergic stimulation of primary cultures of muscle cells results in increased PKA phosphorylation of mAKAPβ-associated RyR2 (Pare, Bauman, et al. 2005). PKA-catalyzed RyR2 phosphorylation increases local Ca in the vicinity of the mAKAPβ signalosome during conditions of increased exchange stimulation. 2+ The release may be enhanced.

[0024] Although it is unlikely that a small number of mAKAPβ-associated RyR2 could affect overall contraction, perinuclear Ca 2+ A possible target for increase is the scaffold-binding Ca 2+Calcineurin (CaN), a calmodulin-dependent phosphatase, is a key phosphatase for CaN. Three isoforms of the catalytic subunit of CaN exist (α, β, γ), but only CaNAβ-mAKAPβ complexes have been detected in myocytes (Li et al. 2010). Notably, CaNAβ is the CaNA isoform that is important for inducing cardiac hypertrophy in vivo and for myocyte survival after ischemia (Bueno et al. 2002; Bueno et al. 2004). CaNAβ directly binds to a unique site (residues 1286-1345) in mAKAPβ (Pare, Bauman, et al. 2005; Li et al. 2010). CaNAβ binding to mAKAPβ is induced by adrenergic stimulation and Ca 2+ CaNAβ-mAKAPβ binding is directly enhanced in cells by calmodulin (Li et al. 2010). Notably, CaNAβ-mAKAPβ binding was required for α-adrenergic-induced neonatal myocyte hypertrophy in vitro (Li et al. 2010).

[0025] mAKAPβ and gene expression CaN is responsible for the activation of NFATc and MEF2 transcription factors, among other substrates. The NFATc transcription factor family contains four CaN-dependent isoforms, all of which are expressed in muscle cells and may contribute to the induction of muscle cell hypertrophy (Wilkins et al. 2004). In general, NFATc family members are retained in the cytoplasm when they are heavily phosphorylated at multiple serine-rich motifs in the N-terminal regulatory domain. When this motif is dephosphorylated by CaN, NFATc translocates into the nucleus. Multiple NFATc family members can bind mAKAPβ, and binding to mAKAPβ was required for CaN-dependent dephosphorylation of NFATc3 in muscle cells (Li et al. 2010). Thus, mAKAPβ expression was also required for NFAT nuclear translocation and transcriptional activity in vitro (Li et al. 2010;Pare, Bauman, et al. 2005). These results correlate with recent findings that NFAT-dependent gene expression in vivo was suppressed by cardiomyocyte-specific knockout of mAKAPβ after aortic coarctation surgery (Kritzer et al. 2014).

[0026] Like NFATc2 and NFATc3, MEF2D is a transcription factor required for cardiac hypertrophy in vivo (Kim et al. 2008;Wilkins et al. 2002;Bourajjaj et al. 2008). MEF2 family members contain a conserved DNA-binding domain that contains both MADS boxes and MEF2 homology domains (Potthoff and Olson 2007). The DNA-binding domain of MEF2D directly binds to the N-terminal domain of mAKAP (Vargas et al. 2012;Kim et al. 2008). CaN and MEF2D are important not only in the heart but also in skeletal muscle (Naya et al. 1999;Naya and Olson 1999;Black and Olson 1998;Friday et al. 2003;Wu et al. 2001). Interference with MEF2-mAKAPβ binding blunted MEF2 transcriptional activity and endogenous MEF2 target gene expression in C2C12 skeletal myoblasts (Vargas et al. 2012). Moreover, inhibition of MEF2-mAKAP complexes suppressed differentiation of C2C12 myoblasts into myotubes, as revealed by reduced cell fusion and differentiation marker expression (Vargas et al. 2012). Of note, CaN-MEF2 binding is mAKAPβ-dependent in cardiomyocytes (Li, Vargas, et al. 2013). Accordingly, inhibition of CaN-mAKAPβ binding inhibited both MEF2 transcriptional activity and cardiomyocyte hypertrophy in C2C12 cells (Li, Vargas, et al. 2013). Like NFATc2, MEF2D dephosphorylation in vivo in response to pressure overload was abrogated following conditional knockout of mAKAPβ and correlated with reduced expression of MEF2 target genes, including atrial natriuretic factor expression (Kritzer et al. 2014).

[0027] Regulation of NFATc, MEF2, and HDAC4 by mAKAPβ during pressure overload in vivo indicates the importance of mAKAPβ for stress-regulated gene expression (Kritzer et al. 2014). Published articles show how mAKAPβ regulates NFATc and MEF2 by CaN, while HDAC4 and HDAC5 by PKD and PKA (Li, Vargas, et al. 2013;Zhang et al. 2013;Li et al. 2010;Dodge-Kafka et al. 2018). mAKAPβ is recognized to facilitate the regulation of these gene regulatory proteins by other signaling enzymes. For example, mAKAPβ-associated ERK5 can phosphorylate MEF2, activating the transcription factor (Kato et al. 2000). Moreover, PKA can phosphorylate MEF2, affecting its DNA-binding affinity (Wang et al. 2005), whereas Olson et al. have proposed that PKA phosphorylation of HDAC4 can inhibit MEF2 activity by generating new HDAC4 proteolytic fragments (Backs et al. 2011). How the activities of multiple mAKAPβ binding partners are ultimately integrated to control gene expression can be studied both in vitro and in vivo.

[0028] Other mAKAPβ binding partners There are other binding partners of mAKAPβ whose docking to the scaffold is not well characterized, including myopodin and NCX1 (Faul et al. 2007; Schulze et al. 2003). HIF-1α, a transcription factor that regulates the systemic response to hypoxia, also binds mAKAPβ (Wong et al. 2008). Under normoxic conditions, the abundance of HIF-1α in cells is kept low by ubiquitin-mediated proteasomal degradation. HIF-1α is hydroxylated by a family of oxygen-sensitive dioxygenases called prolyl hydroxylases (PHD1, PHD2, and PHD3) (Ohh et al. 2000). Hydroxylated HIF-1α is then recognized by von Hippel-Lindau protein (pVHL), which recruits the Elongin C ubiquitin ligase complex to ubiquitinate HIF-1α and promote its proteasome-dependent degradation (Maxwell et al. 1999). Under hypoxic conditions, PHD is inactivated, HIF-1α degradation is reduced, and HIF-1α accumulates in the nucleus where it can dimerize with HIF-1β to promote the transcription of target genes. mAKAPβ can assemble a signaling complex containing HIF-1α, PHD, pVHL, and the E3 ligase Siah2 (seven in absentia homolog 2) in cultured neonatal myocytes (Wong et al. 2008). Under normoxia, mAKAPβ anchors PHD and pVHL to promote HIF-1α ubiquitination and degradation (Wong et al. 2008). However, under hypoxic conditions, Siah2 activation induces proteasomal degradation of bound PHDs and promotes HIF-1α accumulation (Wong et al. 2008). mAKAPβ knockout can affect cardiomyocyte survival after ischemia-reperfusion.

[0029] mAKAPβ - the orchestrator of remodeling organization The above description shows how multiple signaling pathways known to be important in cardiac hypertrophy and pathological remodeling are regulated by the binding of key signaling intermediates to the mAKAPβ scaffold. Cardiomyocyte-specific mAKAP conditional knockout mice have been characterized, showing the association of the mAKAPβ signalosome in vivo (Kritzer et al. 2014). mAKAPβ was required for the induction of cardiac hypertrophy in cardiomyocytes by aortic coarctation and isoproterenol infusion. However, most notable was the prevention of pathological remodeling, including myocardial apoptosis and interstitial fibrosis, and the protection of cardiac function in the face of chronic pressure overload, both of which significantly extended the survival of mice (Kritzer et al. 2014). These results identify mAKAPβ as the first scaffold whose loss confers a survival benefit in cardiac disease. Importantly, mAKAPβ was not found to be required for either the development or maintenance of normal adult cardiac function, as the use of Nkx2-5-targeted cre deletions resulted in no obvious phenotype at 6 months of age (Kritzer et al. 2014). Although mAKAPβ knockout suppresses physiological hypertrophy induced by forced exercise (swimming), targeting the mAKAPβ complex in disease remains relevant.

[0030] Various methods of targeting mAKAPβ complexes in humans can be envisioned, including siRNA knockdown of the scaffold. However, a relatively detailed understanding of the structure and function of the mAKAPβ signalosome provides additional approaches to target these pathways. For example, expression of peptides targeting key protein-protein interactions involved in mAKAPβ, including anchoring disruptor peptides targeting mAKAPβ-CaNAβ, mAKAPβ-MEF2D, mAKAPβ-PLCε, and mAKAPβ-RSK3 binding, has already been shown to be effective in vitro (Li, Vargas, et al. 2013; Li, Kritzer, et al. 2013; Vargas et al. 2012; Zhang et al. 2011). Heart failure, a leading cause of death, is a disease that costs over $30 billion / year in the United States alone and leads to a 50% mortality rate within 5 years of diagnosis even with modern treatments (Go et al. 2014). Many of the possible candidates of targets in cardiac disease are multifaceted, which complicates the development of drugs with sufficient specificity in vivo.Specific targeting of mAKAPβ signalosome provides the opportunity to target relatively rare protein-protein interactions that are recognized as specific to pathological cardiac remodeling and can be promoted to disappear without significant side effects.There is a real need to develop new effective therapies for treating patients with heart failure, and to prevent its development associated with other cardiovascular diseases, such as coronary artery disease, hypertension, and valvular disease. Summary of the Invention

[0031] The following brief summary is not intended to be inclusive of all features and aspects of the invention, and is not intended to imply that the invention must include all features and aspects described in this summary.

[0032] The present inventors have discovered a method to treat cardiac pathological processes by inhibiting the signaling properties of individual mAKAP signaling complexes using drugs that target specific protein-protein interactions, which offers advantages over conventional therapeutic approaches because it allows for the selective inhibition of defined cellular responses.

[0033] In particular, the inventors have discovered that inhibiting mAKAP-mediated protein-protein interactions can be used to inhibit the ability of mAKAP to regulate the activation of enzymes that play a central role in the activation of key transcription factors that initiate the cellular processes that lead to pathological cardiac remodeling.

[0034] Specifically, the inventors have discovered that inhibiting the binding interaction between PP2A and mAKAPβ can protect the heart from damage leading to heart failure, for example after myocardial infarction.

[0035] Thus, in certain embodiments, the present invention includes a method of protecting the heart from damage by administering a pharmacologic effective amount of a composition that inhibits the interaction between PP2A and mAKAPβ to a patient at risk of such damage.

[0036] The present invention also relates to methods for treating cardiac disease by administering to a patient a pharma- ceutical effective amount of a composition that inhibits the interaction between PP2A and mAKAPβ.

[0037] The present invention also relates to a composition that inhibits the interaction between PP2A and mAKAPβ.

[0038] In yet other embodiments, the inhibitor includes any molecule that inhibits the expression or activity of PP2A and mAKAPβ.

[0039] The above and other objects, features and advantages of the present invention will become apparent from the following more particular description of preferred embodiments of the invention, as illustrated in the accompanying drawings in which like reference characters refer to the same parts in the various drawings, and in which the drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention.

[0040] This patent or application contains at least one color drawing. Copies of this patent or patent application publication containing color drawing(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]

[0041] [Figure 1] Figure 1 shows a model of mAKAPβ-regulated, SRF-dependent gene expression. Anchored RSK3 is a Gq protein-coupled receptor-ERK effector that phosphorylates SRF associated with the perinuclear mAKAPβ complex. mAKAPβ-anchored PP2A, which can be activated by cAMP-dependent protein kinase A (PKA), counters SRF phosphorylation. Phosphorylated SRF induces gene expression that promotes concentric hypertrophy. [Diagram 2] FIG. 2 shows the amino acid sequence of human RSK3 (SEQ ID NO:1). [Diagram 3] Figure 3 shows the amino acid sequence of rat mAKAP (SEQ ID NO:2). It is noted that within this document, references to the mAKAP sequence, whether written as "mAKAPβ" or "mAKAP", are by numbering of the mAKAPα alternative splice form, which includes the entire mAKAPβ and is identical to the originally described mAKAP sequence as shown in this figure (Kapiloff 1999, Michel 2005). "mAKAP" is also referred to as "AKAP6" in reference databases and literature. mAKAPβ begins at residue 245, while mAKAPα begins at residue 1. The PP2A binding domain begins at residue 2134. [Figure 4]4 shows the amino acid sequence of the PBD of rat mAKAP when expressed in an AAV vector, including the N-terminal myc tag (SEQ ID NO: 12). [Diagram 5] FIG. 5 shows the plasmid of the PBD of pscA-TnT-myc-rat mAKAP used to generate the AAV9sc.rat PBD (SEQ ID NOs: 13 and 14). [Figure 6] Figure 6 shows the perinuclear scaffolding mAKAPβ. Top: Mouse heart sections (left ventricle) stained with mAKAP antibody (grayscale panels and green), Hoechst nuclear stain (blue), and wheat germ agglutinin (red, shown only in the zoomed control image). Bottom left panel is from a control, mAKAP knockout mouse. Horizontal bar = 20 μm. Center: Adult rat myocytes stained with antibodies against mAKAP (green) and actinin (red). Bottom: mAKAP domain structure. Direct binding partners whose sites are fine-mapped in mAKAPβ are shown. mAKAPβ starts at residue 245 of mAKAPα, i.e. all binding sites are numbered relative to mAKAPα. Image from Kritzer et al. (Kritzer et al. 2014). [Figure 7] Figure 7 shows the signaling modules of mAKAPβ. mAKAPβ binds multiple signaling enzymes and gene regulatory proteins. Modules involved in cAMP, Ca2+, hypoxia, phosphatidylinositide, and MAPK signaling can be defined. See above for details. In this figure, the mAKAPβ scaffold is shown as a yellow sphere placed on a grey base representing nesprin-1α and associating various signaling molecules. The gold cylinder represents the nuclear pore complex that is inserted into the nuclear membrane. [Figure 8]FIG. 8 shows that okadaic acid-sensitive phosphatases regulate mAKAP-associated PDE4D3. A, Transfected HEK293 cells expressing both mAKAP and PDE4D3 were treated with either 300 μM okadaic acid (OA) or 500 μM cyclosporine A (CsA) for 30 min, followed by stimulation with 5 μM forskolin (Fsk) for 10 min. The phosphorylation state of PDE4D3 present in mAKAP antibody immunoprecipitates was measured using an antibody specific for Ser-54 of phosphorylated PDE4D3 (top panel). Total PDE4D3 (middle panel) and mAKAP (bottom panel) present in mAKAP antibody immunoprecipitates were detected using a non-phospho-specific antibody. It is noted that in these experiments, mAKAP was GFP-tagged and PDE4D3 was VSV- and GFP-tagged, with increased molecular weight. n=3. B, PDE activity associated with mAKAP antibody immunoprecipitates prepared as in A was assayed using [3H]cAMP substrate. *p<0.05 compared to untreated cells (bar 1). C, Endogenous protein complexes were isolated from clarified adult rat heart extracts (500 μg total protein) using control (IgG) or mAKAP-specific antibodies. PDE activity associated with the immunoprecipitates was assayed in the presence of 10 nM OA or 50 nM PKI. n=3, *p<0.05. [Figure 9]FIG. 9 shows that protein phosphatase PP2A associates with the mAKAP scaffold in adult rat heart. A, Phosphatase activity associated with protein complexes immunoprecipitated with mAKAP antibodies from adult rat heart extracts (500 μg total protein) was assayed using 32P-labeled histone substrate with or without 30 nM PP2A inhibitor I (Li, Makkinje, and Damuni 1996) and 100 nM PKA phosphorylation PP1 inhibitor-1 (Endo et al. 1996). n=3. *p<0.05. B and C, Protein complexes were isolated from clarified adult rat heart extracts (2 mg total protein) using control (IgG) or mAKAP-specific antibodies. PP2A (panel B) and PP1 (panel C) catalytic subunits in extracts (80 μg) and immunoprecipitates (25% loading) were detected by immunoblotting. n=3. [Figure 10]Figure 10 shows that PP2A binds the C-terminal mAKAP domain. A, Schematic diagram of the mAKAP domain and GFP- and myc-tagged mAKAP proteins used herein. mAKAP fragments containing the rat and human proteins are shown in black and grey, respectively. The hatched bars indicate three spectrin repeat domains that are responsible for nuclear membrane targeting in muscle cells (Kapiloff et al. 1999a). Binding sites are shown for proteins known to directly bind mAKAP, including 3-phosphoinositide-dependent kinase-1 (PDK1, mAKAP residues 227-232) (Michel et al. 2005b), nesprin-1α (1074-1187) (Pare, Easlick, et al. 2005), ryanodine receptor (RyR2, 1217-1242) (Marx et al. 2000), PP2B (1286-1345) (Li et al. 2009), PDE4D3 (1285-1833) (Dodge et al. 2001), and PKA (2055-2072) (Kapiloff et al. 1999a). Shaded bars indicate the PP2A binding site. The first and last residues of each fragment are indicated. B, Purified GST-PP2A A subunit fusion proteins were incubated with extracts prepared from HEK293 cells expressing the indicated GFP-mAKAP fusion proteins and detected by pull-down using glutathione resin. GFP-mAKAP fragments were detected in pull-downs (25% loading, top panel) and extracts (5% loading, bottom panel) using GFP antibody. n=3. C, myc-tagged mAKAP fragments were expressed in HEK293 cells and phosphatase binding was detected by immunoprecipitation with control (IgG) or myc-tagged antibodies followed by phosphatase assay using 32P-labeled histone substrate. n=3. *p<0.05 compared to other samples. It is noted that the C-terminal homology domains of both rat and human mAKAP bind PP2A. [Figure 11]FIG. 11 shows that the association of PP2A with the mAKAP-PDE4D3 complex is required for the inhibition of PDE4D3 phosphorylation. A, HEK293 cells expressing PDE4D3 (VSV and GFP tagged) and myc-tagged mAKAP1286-2312 or 1286-2083 lacking the PP2A binding site were treated with 300 μM OA for 30 min followed by stimulation with 5 μM Fsk for 10 min. Protein complexes were immunoprecipitated using myc-tagged antibodies in the presence of phosphatase inhibitors. The phosphorylation state of co-immunoprecipitated PDE4D3 was measured using an antibody specific for Ser-54 of phosphorylated PDE4D3 (P-PDE4D3, top panel). Total PDE4D3, myc-mAKAP, and PP2A C-subunit present in the immunoprecipitates were detected using non-phospho-specific antibodies (lower three panels). n=3. B, PDE activity associated with myc antibody immunoprecipitates isolated from additional cells treated as in A was assayed using [3H]cAMP. n=3. *p<0.05 compared to bar 1. [Figure 12]FIG. 12 shows that mAKAP-associated PP2A contains the B56δ subunit and is cAMP-activated. A, Protein complexes were immunoprecipitated from adult rat heart extracts (500 μg total protein) using control (IgG) or mAKAP-specific antibodies as in FIG. 2B and assayed for associated phosphatase activity. Immunoprecipitates were preincubated for 5 min without or with 50 μM CPT-cAMP, 10 nM OA, or 50 nM PKI, as indicated, prior to the addition of [32P]histone substrate. n=3. *p<0.05. B, Endogenous protein complexes were immunoprecipitated from adult heart extracts (2 mg total protein) with B56δ and control (IgG) antibodies. mAKAP in 80 μg extracts and immunoprecipitates (25% loading) was detected by immunoblotting. n=3. C, Flag-tagged B56δ and / or GFP-tagged mAKAP were expressed in HEK293 cells. Protein complexes were immunoprecipitated using mAKAP antibody. B56δ in immunoprecipitates (25% loading) and total extracts (5% loading) was detected with Flag antibody by immunoblotting. n=3. D, Phosphatase activity associated with mAKAP antibody immunoprecipitates prepared as in C was assayed using 32P-labeled histone substrate. n=3. E, HEK293 cells expressing mAKAP and B56δ were treated with 5 μM Fsk and 10 μM IBMX (Fsk / IBMX) for 10 min, followed by immunoprecipitating protein complexes with mAKAP antibody. Phosphatase activity associated with immunoprecipitates was assayed using [32P]histone substrate. n=3. It is noted that B56δ and C subunit binding of PP2A to mAKAP was not affected by Fsk / IBMX (see FIG. 13 below). [Figure 13]Figure 13 shows that phosphorylation of B56δ by PKA increases mAKAP-associated PP2A activity. A, B56δ is phosphorylated by PKA at serine residues 53, 68, 81, and 566 (Ahn et al. 2007). Wild-type or alanine-substituted (S4A) B56δ at all four PKA sites was coexpressed in HEK293 cells with wild-type mAKAP or a full-length mAKAP mutant lacking the PKA binding site (ΔPKA, see Figure 3A). After stimulation with 5 μM Fsk and 50 μM IBMX, protein complexes were immunoprecipitated with mAKAP antibodies, and associated proteins were detected by immunoblotting with B56δ, mAKAP, and PP2A-C antibodies (lower three panels). PKA phosphorylation of B56δ was detected by immunoblotting with a B56δ phospho-Ser-566 specific antibody (P-B56δ, upper panel). n=3. B, Immunoprecipitates prepared in B were assayed for associated phosphatase activity. n=3. *p<0.05. [Figure 14] FIG. 14 shows that phosphorylation of B56δ by PKA enhances dephosphorylation of mAKAP-associated PDE3D3. A, HEK293 cells expressing mAKAP (GFP-tagged), PDE4D3 (VSV- and GFP-tagged), and either wild-type B56δ or the B56δ S4A mutant of the PKA phosphorylation site were treated with 300 μM OA for 30 min as indicated, followed by stimulation with 5 μM Fsk for 10 min. Protein complexes were immunoprecipitated with mAKAP antibodies in the presence of phosphatase inhibitors. The phosphorylation state of PDE4D3 present in the immunoprecipitates was measured using an antibody specific for Ser-54 of phosphorylated PDE4D3 (top panel). Total PDE4D3, mAKAP, B56δ, and PP2A-C proteins present in the immunoprecipitates were detected using non-phospho-specific antibodies (bottom four panels). n=3. B, PDE activity associated with protein complexes isolated from additional cells treated as in A was assayed using [3H]cAMP. n=3. *p<0.05 compared to bar 1. [Figure 15]FIG. 15 shows that PKA and PP2A associated with the mAKAP complex cooperate to regulate PDE4D3 activity and cAMP degradation. PKA is composed of two regulatory subunits and two catalytic subunits. mAKAP-bound PP2A contains A, B56δ, and C (catalytic) subunits. A, in unstimulated cells, basal PP2A activity maintains PDE4D3 dephosphorylation, presumably resulting in a more rapid rise in cAMP levels in response to subsequent agonists than would occur if PDE4D3 were phosphorylated and activated. At the same time, basal PDE4D3 activity should keep local levels of cAMP low, preventing spurious signaling. B, Gs-coupled receptor stimulation induces cAMP synthesis, exceeding the rate of cAMP degradation by PDE4D3, activating mAKAP-bound PKA. PKA phosphorylates and activates both PDE4D3 and PP2A. PDE4D3 activity should limit peak cAMP levels and accelerate the rate of cAMP clearance following GPCR downregulation, whereas PP2A activation opposes PDE4D3 phosphorylation by PKA, reducing cAMP degradation and contributing to a greater and longer-lasting cAMP signal. [Figure 16] Figure 16 shows confirmation of inhibition of PP1 activity by PKA phosphorylation I-1. Protein complexes were immunoprecipitated from rat heart extracts with PP1 or control IgG antibodies, and associated phosphatase activity was assayed using [32P]histone substrate with or without 100 nM PKA phosphorylation PP1 inhibitor-1 (Endo et al. 1996). n=3. [Figure 17]FIG. 17 shows the distribution of mAKAP and PP2A catalytic subunits in neonatal rat cardiomyocytes. Neonatal rat ventricular myocytes were isolated as previously described (Pare, Easlick, et al. 2005). After treatment with 50 μM phenylephrine for 1 week to induce myofibrillar organization and mAKAP expression, cells were fixed and stained with 0.25 μg / ml mouse anti-PP2A-C (green), 0.1 μg / ml OR010 rabbit anti-mAKAP (red) affinity purified antibodies, and rhodamine phalloidin (blue in composite image) to show actin myofibrils, as previously described. Four-color images were obtained at 400× on a Zeiss LSM510 / UV confocal microscope. For clarity, separate PP2A-C subunit and mAKAP images are shown. The PP2A-C subunit is present in a diffuse punctuate pattern in the cytosol, while mAKAP is restricted to the nuclear membrane location. The presence of PP2A-C subunit staining at the nuclear membrane is consistent with the presence of a PP2A-mAKAP complex (yellow in the composite image). Control IgG staining is shown in the right panel. n=3. [Figure 18] Figure 18 shows that mAKAP fragments do not bind to PP1 in HEK293 cells. mAKAP-GFP fusion protein was expressed in HEK293 cells and the protein complex was immunoprecipitated with PP1 antibody. Despite strong expression (lower panel), mAKAP fusion protein was not precipitated with PP1 antibody. n=3. [Figure 19]Figure 19 shows that SRF phosphorylation is regulated by the mAKAPβ signalosome in cardiomyocytes. (A) SRF domain structure. Known phosphorylation residues are indicated (Li et al. 2014; Mack 2011; Janknecht et al. 1992). (B) Neonatal rat ventricular myocytes (NRVMs) were transiently transfected with siRNA and SRE-luciferase and control Renilla luciferase plasmids. Normalized luc:rluc ratios are shown. n=3. (C) Co-immunoprecipitation of endogenous complexes from mouse heart extracts. n=3. (D) HA-tagged RSK3WT or S218A inactive mutant (Li, Kritzer, et al. 2013) and / or myc-mAKAPβ were expressed in COS-7 cells for co-immunoprecipitation assays. n=3. (E) NRVM extracts were obtained 2 days after transfection with siRNA with or without 10 μM PE. See Fig. S1B. n=3. * for control siRNA+PE, † for control siRNA+no drug. (F) Adult rat ventricular myocytes (ARVM) were infected with adenovirus expressing myc-GFP or myc-GFP-RBD and treated with 20 μM PE for 1 day. n=3. * for myc-GFP+PE, † for myc-GFP+no drug. (G) NRVM in minimal maintenance medium were treated with 1 μM okadaic acid (OA) or 1 μg / ml cyclosporine A (CsA) for 1 h. n=4. * for no drug control. (H) NRVM transfected with control or mAKAP siRNA were used for co-immunoprecipitation assays. PP2A holoenzyme contains a homodimeric core of A and C subunits and a scaffolding B subunit (Dodge-Kafka et al. 2010). PP2A C subunit (PP2A-C) was detected by immunoblotting. n=3. (I) NRVM were infected with adenovirus expressing myc-PBD or β-gal followed by co-immunoprecipitation assay. n=3. (J) ARVM were infected with myc-PBD or β-gal adenovirus and treated with 10 μM Iso for 1 day. n=4. * for β-gal+Iso, † for β-gal+no drug. [Figure 20] FIG. 20 shows that SRF S103 phosphorylation is a determinant of myocyte centripetal growth. Adult rat ventricular myocytes (ARVMs) were infected with adenovirus and cultured with or without 20 μM PE or 10 μM Iso for 24 h, followed by immunocytochemical staining and measurements of cell width and length (maximum dimension parallel to or perpendicular to the striations, horizontal line=25 μm). (A,B) Myocytes were infected with adenovirus expressing β-gal (control) or HA-tagged RSK3 and maintained in minimal medium. At the top, α-actinin-red, nuclei-blue, HA-RSK3-green, at the bottom, HA-RSK3-grayscale. n=4. (C-F) Myocytes were infected with adenovirus expressing SRF WT, S103D, S013A, or control virus. Flag-SRF-green, α-actinin-red, nuclei-blue. * vs. same virus, no drug, † vs. control under the same treatment conditions, ‡ vs. SRF WT under the same treatment conditions. D: n=3, F: n=5. (G,H) Myocytes were infected with adenovirus expressing myc-GFP or myc-GFP-RBD (green). (I,J) Myocytes were infected with adenovirus expressing myc-PBD or β-gal control. (G-J) α-actinin-red, nuclei-blue. * vs. same protein, no drug control, † vs. control protein under the same treatment conditions. n=4. Relative frequency distributions of cells measured in these experiments are shown in Fig. S4. [Figure 21] Figure 21 shows that PP2A dephosphorylates SRF S103. GST-SRF fusion protein purified from bacterial extracts and plated onto glutathione beads was incubated with 0.5 μg of purified RSK3 (Millipore) for 30 min, then washed twice with PP2A reaction buffer and incubated with 50 ng of purified PP2A with or without 10 nM okadaic acid for 30 min. [Figure 22]Figure 22 shows AAV9sc.myc-PBD. A. AAV9sc.myc-PBD contains a minigene expressing myc-tagged rat PBD peptide (rat mAKAP aa 2134-2314) and a deleted right ITR, providing self-complementation and possibly reducing delay and increasing expression efficiency (Andino et al., 2007). AAV has a cardiotrophic serotype 9 capsid protein and expresses the encoded protein under the control of the cardiomyocyte-specific tritroponin T promoter (cTnT) (Prasad et al., 2011). B. Shuttle plasmid for AAV9sc.myc-PBD is shown. [Diagram 23] FIG. 23 shows PBD anchoring disruptor treatment. (A) myc-tagged rat mAKAP PBD (AAV9sc.myc-PBD) and myc-GFP (AAV9sc.GFP) were expressed in mice using self-complementary AAV9 and the cardiomyocyte-specific tritroponin T promoter (Prasad et al., 2011). (B) Time course of AAV9sc.myc-PBD treatment study is shown in C-H. Mice were 8 weeks old at the start of the study. (C) Representative whole heart photographs at endpoint are shown. Horizontal bar = 5 μm. (D-H) Sequential M-mode echocardiograms are shown. n is AAV9sc.myc-PBD-8 (green), AAV9sc.GFP-5 (black). *P value for difference between cohorts at a given time point. LV remodeling index = mass ÷ end-diastolic volume. LVAW; d-left ventricular anterior wall thickness in diastole. [Figure 24] FIG. 24 shows the nucleotide sequence of human RSK3 (SEQ ID NO:15). [Diagram 25] FIG. 25 shows the nucleotide sequence of the rat mAKAPα mRNA translated open reading frame (SEQ ID NOs: 2 and 16). [Figure 26] FIG. 26 shows the nucleotide sequence of the human mAKAPβ mRNA translated open reading frame (SEQ ID NOs: 17 and 18). [Figure 27]FIG. 27 shows the nucleotide sequence of the human mAKAPα mRNA translated open reading frame (SEQ ID NOs: 19 and 20). [Figure 28] Figure 28 shows the amino acid sequence of human mAKAP (SEQ ID NO:8). mAKAPα starts at residue 1 and mAKAPβ starts at residue 243. The PBD is shown in bold. [Figure 29] FIG. 29 shows the amino acid sequence of the human PBD expressed in AAV (SEQ ID NO:9). [Diagram 30] Figure 30 shows an alignment of the amino acid sequences of the human and rat PBDs expressed in AAV species (SEQ ID NOs: 9 and 12). The rat PBD has an N-terminal Myc-tag [EQKLISEEDL] (SEQ ID NO: 21) (Figure 4). [Diagram 31] FIG. 31 shows the map of the human PBD shuttle plasmid. [Diagram 32] FIG. 32 shows the nucleotide sequence of the pscAAV-hmAKAP PBD plasmid (SEQ ID NOs: 10 and 11). [Diagram 33]FIG. 33 shows that SRF phosphorylation is decreased in dilated hearts. (A-E) Protein extracts of mouse ventricles were assayed for phosphorylated and total SRF 5 min (short-term pressure overload, n=4,4) or 16 weeks (heart failure, n=15,19) after TAC or sham survival surgery. (A) Representative Western blots are shown. (B) Densitometry of the top panel of A is shown. (C) Five minutes after pressure overload, RSK3 was immunoprecipitated using N-16 RSK3-specific antibody and detected using OR43 RSK3 antibody and RSK3 S218 phospho-specific antibody, indicating RSK3 activity. Immunoprecipitation-Western assays were validated using RSK3- / - mice (not shown). n=3 in each condition. (D) Heart failure was induced by pressure overload for 16 weeks. M-mode echocardiography for left ventricular (LV) volumes in diastole and systole as well as ejection fraction showed that TAC hearts were dilated and dysfunctional. Measurement of edema lung weight (coupled to tibia length) indicating the presence of pulmonary edema showed that TAC mice had heart failure. (E) Densitometry of the lower panel of A is shown. (F-H) Left ventricular tissue from human patients (including nonischemic and ischemic cardiomyopathies and nondilated congenital heart disease and controls) was assayed for SRF S103 phosphorylation and separated by normal (<5.3 cm, n=7) or elevated (>5.3 cm, n=8) left ventricular internal diameter (LVID; d) in diastole. Equal loading in blots was confirmed using Ponceau S staining of the major protein bands (not shown). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0042] As mentioned above, AKAP-derived signaling complexes play a central role in regulating physiological and pathological cardiac events. Therefore, the present inventors have investigated the inhibition of the signaling properties of individual AKAP signaling complexes using drugs that target specific protein-protein interactions as an approach to suppress cardiac pathological processes. Such a therapeutic method offers advantages over conventional therapeutic approaches, since it allows selective inhibition of a given cellular response.

[0043] Anchor proteins, including mAKAP, are therapeutic targets for the treatment of cardiac hypertrophy and heart failure. In particular, the present inventors have discovered that inhibiting AKAP-mediated protein-protein interactions can be used to inhibit the ability of mAKAP to regulate the activation of enzymes that play a central role in the activation of key transcription factors that initiate the remodeling process that leads to cardiac hypertrophy.

[0044] One aspect of the present invention is that improving ventricular geometry, i.e., reducing LV internal diameter with less elongated myocytes and / or increasing LV wall thickness with wider myocytes, may reduce wall stress (Laplace's Law) and improve systolic function in HFrEF-prone hearts. Prevention of systolic dysfunction has been shown in a new gene therapy vector based on expression of muscle A-kinase anchoring protein (mAKAP, also known as AKAP6)-derived anchoring disruptor peptide of protein phosphatase 2A (PP2A).

[0045] As described below, the present inventors demonstrated that the transcription factor serum response factor (SRF) is mediately activated by RSK3 at the mAKAPβ signalosome in cardiomyocytes. 103 We recently discovered that SRF is phosphorylated by SRF, which can then be dephosphorylated by scaffold-bound protein phosphatase 2A (PP2A). Methods for inhibiting the eccentric changes in ventricular morphology that characterize end-stage disease and HFrEF are the subject of the present invention.

[0046] Protein phosphatase 2A (PP2A), previously thought to be a constitutive housekeeping enzyme, has been shown to contribute to the regulation of many phosphorylation events. For example, in cardiomyocytes, PP2A is involved in the regulation of calcium and MAPK signaling (duBell, Lederer, and Rogers 1996; duBell et al. 2002; Liu and Hofmann 2004). PP2A is a serine / threonine phosphatase that exists as a stable, ubiquitously expressed heterodimer of catalytic (PP2A-C) and scaffolding (PP2A-A) subunits, as well as a heterotrimeric complex consisting of one of 21 known diverse B subunits (Lechward et al. 2001; Wera and Hemmings 1995). PP2A B subunits are classified into three unrelated families, designated B (or PR55), B' (or B56) and B'' (or PR72), and have been proposed to regulate both catalytic activity and intracellular targeting of the phosphatase (Virshup 2000). We have previously shown by reconstitution of the mAKAP complex in heterologous cells that protein phosphatase 2A (PP2A), which associates with the mAKAP complex, can reverse PDE4D3 activation by catalyzing the dephosphorylation of PDE4D3 serine residue 54 (Dodge-Kafka et al. 2010). Mapping studies revealed that the C-terminal mAKAP domain (residues 2085-2319) binds PP2A (Dodge-Kafka et al. 2010). Binding to mAKAP was required for PP2A function at PDE4D3, such that deletion of the C-terminal domain enhanced both baseline and forskolin-stimulated PDE4D3 activity. Interestingly, PP2A holoenzyme associated with mAKAP complexes in the heart contains the PP2A targeting subunit B56δ (Dodge-Kafka et al. 2010). Like PDE4D3, B56δ is a PKA substrate, and PKA phosphorylation of mAKAP-bound B56δ enhanced phosphatase activity twofold in the complex.Thus, expression of a B56δ mutant that cannot be phosphorylated by PKA in heterologous cells bearing mAKAP resulted in increased PDE4D3 phosphorylation. Together, these findings indicated that PP2A associated with the mAKAP complex functions both to promote PDE4D3 dephosphorylation and inhibit PDE4D3 in unstimulated cells, and to mediate a positive feedback loop of cAMP induction following adenylyl cyclase activation and B56δ phosphorylation. Thus, the PKA-PDE4D3-PP2A-mAKAP complex illustrates how protein kinases and phosphatases can participate in molecular signaling complexes to dynamically regulate localized intracellular signaling. The relevance to cardiomyocyte function and any possible therapeutic implications was not defined in previous studies (Dodge-Kafka et al. 2010).

[0047] The present inventors disclose here a novel mechanism of action of mAKAP-bound PP2A in cardiomyocytes and the therapeutic significance of this mechanism. 103 (Figure 19) and Ser 103 Our results suggest that phosphorylation of SRF in endothelial cells constitutes an epigenetic switch that promotes centripetal cardiomyocyte hypertrophy (Fig. 20). Importantly, the phosphorylation of SRF at Ser 103 We disclose that SRF can be dephosphorylated by PP2A bound to the mAKAPβ scaffold (FIGS. 19 and 21). 103 It has been shown that phosphorylation of PP2A induces concentric myocyte hypertrophy (Figure 20). These findings reveal a new mechanism for regulating cardiomyocyte morphology and an unexpected function for mAKAPβ-bound PP2A. In particular, the inventors have demonstrated that depletion of PP2A from mAKAPβ in vitro inhibits the phosphorylation of Ser of cardiomyocyte SRF, consistent with a role for PP2A as a phosphatase for mAKAPβ-bound SRF. 103 (FIG. 19), and concentric cardiomyocyte hypertrophy (FIG. 20), and can protect against the development of systolic dysfunction after myocardial infarction in mice in vivo (FIG. 23).

[0048] Inhibition of PP2A binding to mAKAPβ can be achieved by expression of a competitor peptide containing mAKAPβ2134-2314 (FIG. 19) or 2132-2319 of human mAKAPβ, which represents a new refinement of PP2A binding site mapping in mAKAPβ and shows for the first time inhibition of mAKAP-PP2A binding in vivo in cardiac disease. It is noted that the C-terminal domain of human mAKAP, which is homologous to that of rat mAKAP, has also been shown to bind PP2A (FIG. 10). Therefore, the human sequence for rat mAKAP2134-2314 (human mAKAP amino acid residues homologous to 2132-2319) shown in FIG. 28-FIG. 30 is also expected to bind PP2A and constitutes a PP2A-mAKAP binding competitor peptide.

[0049] Effective delivery of PP2A anchoring disruptor peptides via virus-based gene therapy has been shown by efficacy in a mouse infarction model (Figure 23). Alternatively, delivery of such peptides that can inhibit PP2A-mAKAPβ interaction can be improved by the use of transactivators of transcription peptides and cell-penetrating sequences such as polyarginine tails or conjugation with lipid-derived groups such as stearates. Stability can also be improved by the use of peptidomimetics (i.e., peptides with structural changes in the original sequence that provide protection against exo- and endoproteases without affecting the structural and functional properties of the peptide).

[0050] The inventors have also found that small molecule disruptors can be used to target specific interactions within AKAP-derived complexes. Small molecule disruptors can be identified by combining rational design and screening methods. Such compounds can be designed to target specific binding surfaces of AKAPs, inhibit the interaction of AKAPs with PP2A in cardiomyocytes, and improve normal cardiac contraction for the treatment of chronic heart failure.

[0051] The present invention relates to a method for treating any cardiac pathology caused by the interaction of PP2A and mAKAPβ. Such cardiac dysfunction can result in signs and symptoms such as shortness of breath and fatigue, and can have a variety of causes, including but not limited to hypertension, coronary artery disease, myocardial infarction, valvular disease, primary cardiomyopathies, congenital heart disease, arrhythmias, pulmonary disease, diabetes, anemia, hyperthyroidism, and other systemic diseases.

[0052] In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art, which are fully explained in the literature. For example, Sambrook et al, “Molecular Cloning: A Laboratory Manual” (4th Ed., 2012); “Current Protocols in Molecular Biology” Volumes I-III [Ausubel, RM, ed. (1994)]; “Cell Biology: A Laboratory Handbook” Volumes I-III [JE Celis, 3rd ed. (2005))]; “Current Protocols in Immunology” Volumes I-III [Coligan, JE, ed. (2005)]; “Oligonucleotide Synthesis” (MJ Gait ed. 1984); “Nucleic Acid Hybridization” [BD Hames & SJ Higgins eds. (1985)]; “Transcription And Translation” [BD Hames & SJ Higgins, eds. (1984)]; Freshney, ed. (1986)]; “Immobilized Cells And B. Perbal, “A Practical Guide To Molecular Cloning” (1984); C. Machida, “Viral Vectors for Gene Therapy: Methods and Protocols” (2010); J. Reidhaar-Olson and C. Rondinone, “Therapeutic Applications of RNAi: Methods and Protocols” (2009).

[0053] The following definitions and abbreviations are used herein: AC5- Adenylyl cyclase type 5 ACE - Angiotensin-converting enzyme ANF- atrial natriuretic factor ARVM- Adult rat ventricular myocytes CaN-calcineurin CArG Box - (CC9AT)6GG CPT- cAMP-8-(4-chlorophenylthio)adenosine 3',5'-cyclic monophosphate CsA- Cyclosporine A CTKD- C-terminal kinase domain ERK- Extracellular signal-regulated kinase FBS- Fetal Bovine Serum Fsk- Forskolin GFP- Green Fluorescent Protein GPCR - G-protein coupled receptor HDAC - Histone deacetylase Gs- stimulatory G protein GST- glutathione-S-transferase HIF1α- hypoxia-inducible factor 1α HFrEF- Heart failure with reduced ejection fraction IBMX- 3-isobutyl-1-methylxanthine Iso-Isoproterenol LIF- leukemia inhibitory factor MADS- (MCM1, agamous, deficiens, SRF) domain-mediates DNA binding to CArG box (CC9AT)6GG serum response element (SRE). The MADS box gene family was later named as an acronym referring to the first four members, ignoring ARG80. MCM1 from the budding yeast Saccharomyces cerevisiae AGAMOUS from Arabidopsis thaliana DEFICIENS FROM SNAPDRAGON ANTIRRHINUM MAJUS SRF from human Homo sapiens mAKAP- Muscle A-kinase anchoring protein mAKAPα - alternatively spliced ​​isoform expressed in neurons, 255 kDa mAKAPβ - alternatively spliced ​​isoform expressed in striated muscle cells, 230 kDa MAPK- Mitogen-activated protein kinase MEF2- Myocyte enhancer factor-2 MgAc - Magnesium Acetate MI- Myocardial infarction NCX1- sodium / calcium exchanger NFATc- Nuclear factor of activated T cells NRVM- neonatal rat ventricular myocytes NTKD - N-terminal kinase domain OA- Okadaic acid PBD-PP2A- Anchoring Disruptor-Inhibits eccentric hypertrophy PDE4D3- cAMP-specific phosphodiesterase type 4D3 PDK1- 3´ phosphoinositide-dependent kinase 1 PE- Phenylephrine PHD - Prolyl hydroxylase PI4P- phosphatidylinositol-4-phosphate PKA- Protein Kinase A PKD- Protein kinase D PKI- Protein Kinase Inhibitors PLCε - phospholipase Cε PKA- cAMP-dependent protein kinase PP2A- Protein (serine-threonine) phosphatase-SRF Ser 103 Dephosphorylates PP2B- calcium / calmodulin-dependent protein phosphatase 2B RBD-isoform-specific N-terminal RSK3 domains bind distinct "RSK3-binding domains" within mAKAPβ at residues 1694-1833 (RBD) RSK- p90 ribosomal S6 kinase RyR2 - type 2 ryanodine receptor siRNA - Small interfering RNA oligonucleotides shRNA - Short Hairpin RNA SRE- Serum response element SRF - Serum response factor-transcription factor (SRF Ser 103 Phosphorylation of induces afferent myocyte and cardiac hypertrophy. Inhibition of phosphorylation improves cardiac structure and function. siRNA - Small interfering RNA TAC- Aortic coarctation TCA - Trichloroacetic acid VSV - vesicular stomatitis virus

[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. In general, the terminology and techniques used in cell and molecular biology and molecular chemistry are well known and commonly used in the art. Specific experimental techniques not specifically specified are generally performed by conventional methods well known in the art and as described in the various general and more specific references cited and described herein. For clarity, the following terms are defined below.

[0055] The present invention recognizes that the interaction between PP2A and mAKAPβ mediates various intracellular signals and pathways that lead to cardiomyocyte hypertrophy and / or dysfunction. Thus, the inventors have discovered various ways of inhibiting this interaction to prevent and / or treat cardiomyocyte hypertrophy and / or dysfunction.

[0056] Thus, the present invention includes a method for protecting heart from damage, which is carried out by administering a pharmacologic effective amount of a composition that inhibits the interaction between PP2A and mAKAPβ to a patient at risk of such damage.It should be understood that "pharmacologic effective amount" can be empirically determined based on the method of delivery and can vary depending on the method of delivery.

[0057] The present invention also relates to methods of treating cardiac disease by administering to a patient a pharma- ceutical effective amount of a composition that inhibits the interaction between PP2A and mAKAPβ.

[0058] The present invention also relates to compositions that inhibit the interaction of PP2A with mAKAPβ. In certain embodiments, these inhibitory compositions or "inhibitors" include peptide inhibitors that can be administered by any known method, including gene therapy delivery. In other embodiments, the inhibitors can be small molecule inhibitors.

[0059] Specifically, the present invention relates to methods and compositions for treating or protecting the heart from injury by administering to a patient at risk of such injury a pharmacologic effective amount of a composition that (1) inhibits the interaction between PP2A and mAKAPβ, (2) inhibits the activity of PP2A and mAKAPβ, or (3) inhibits the expression of PP2A and mAKAPβ.

[0060] The present invention also relates to a method for treating or protecting against heart damage by administering to a patient at risk of such damage a pharmacologic amount of a composition that inhibits cellular processes mediated by PP2A anchoring.

[0061] In one embodiment, the composition comprises mAKAPβ and a peptide. In a preferred embodiment, the mAKAPβ peptide is obtained from the carboxy terminus of the mAKAPβ amino acid sequence. In a particularly preferred embodiment, the mAKAPβ peptide is a fragment of at least amino acids 2083 to 2319 of the mAKAPβ amino acid sequence.

[0062] In a preferred embodiment, the mAKAPβ peptide is a fragment of at least amino acids 2133 to 2319 of the mAKAPβ amino acid sequence.

[0063] In another embodiment, the composition comprises a small interfering RNA siRNA that inhibits expression of either or both of PP2A and mAKAPβ. In a preferred embodiment, the siRNA that inhibits expression of mAKAPβ is generated in vivo after administration of a short hairpin RNA expression vector or a biological agent (shRNA).

[0064] The compositions of the invention can be administered directly or using a viral vector, hi a preferred embodiment, the vector is an adeno-associated virus (AAV).

[0065] In other embodiments, the composition comprises a small molecule inhibitor. In a preferred embodiment, the small molecule is a PP2A inhibitor.

[0066] In another embodiment, the composition comprises a molecule that inhibits the binding, expression or activity of mAKAPβ. In a preferred embodiment, the molecule is a mAKAPβ peptide. The molecule can be expressed using a viral vector, including an adeno-associated virus (AAV).

[0067] In yet other embodiments, the composition comprises a molecule that interferes with a mAKAPβ-mediated cellular process, hi a preferred embodiment, the molecule interferes with the anchoring of PP2A.

[0068] The invention also relates to diagnostic assays for determining a propensity for cardiac disease in which the binding interaction of PP2A with mAKAPβ is measured either directly or by measuring downstream effects of the binding of PP2A with mAKAPβ, and the invention provides test kits for such assays.

[0069] In yet other embodiments, inhibitors include any molecule that inhibits the expression of PP2A and mAKAPβ, including antisense RNA, including shRNA, ribozymes, and small interfering RNA (siRNA).

[0070] The invention also includes assay systems for screening for potential agents effective for inhibiting expression and / or binding of PP2A and mAKAPβ. In one embodiment, a test agent can be administered to a cell sample containing PP2A and mAKAPβ, or an extract containing PP2A and mAKAPβ, to measure its effect on the binding activity of PP2A and mAKAPβ by comparison with a control. The invention also provides test kits for such assays.

[0071] In preparing the peptide composition of the invention, all or part of the amino acid sequence of PP2A or mAKAP (Figure 3) can be used. In one embodiment, the carboxy-terminal region of the mAKAPβ protein is used as the inhibitor. Preferably, at least 10 amino acids of the mAKAP sequence are used. More preferably, at least 25 amino acids of the mAKAP sequence are used. Most preferably, the peptide portion of amino acids 2133 to 2319 of mAKAP is used.

[0072] It should be understood that various amino acid substitutions, deletions, or insertions can also improve the ability of the inhibitor peptide to inhibit the interaction between PP2A and mAKAPβ. Such substitution mutations can be made to change the amino acids of the resulting protein in a non-conservative manner (i.e., by changing an amino acid belonging to an amino acid group having a particular size or characteristic to an amino acid belonging to another group) or in a conservative manner (i.e., by changing an amino acid belonging to an amino acid group having a particular size or characteristic to an amino acid belonging to the same group). Such conservative changes generally result in less change in the structure and function of the resulting protein. Non-conservative changes are more likely to change the structure, activity, or function of the resulting protein. It should be considered that the present invention includes sequences that contain conservative changes that do not significantly change the activity or binding characteristics of the resulting protein.

[0073] Below are some examples of different amino acid classifications: Nonpolar R group amino acids: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine. Amino acids with polar uncharged R groups: glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine. Amino acids with polar charged R groups (negatively charged at pH 6.0): aspartic acid, glutamic acid. Basic amino acids (positively charged at pH 6.0): lysine, arginine, histidine (at pH 6.0).

[0074] Another classification could be amino acids with a phenyl group: phenylalanine, tryptophan, tyrosine.

[0075] Other classifications can be by molecular weight (i.e., size of the R group): glycine (75), alanine (89), serine (105), proline (115), valine (117), threonine (119), cysteine ​​(121), leucine (131), isoleucine (131), asparagine (132), aspartic acid (133), glutamine (146), lysine (146), glutamic acid (147), methionine (149), histidine (at pH 6.0) (155), phenylalanine (165), arginine (174), tyrosine (181), tryptophan (204).

[0076] Particularly preferred substitutions are - Lys to Arg and vice versa, so as to be able to maintain a positive charge; - Glu to Asp and vice versa, so as to be able to maintain a negative charge; - Ser to Thr, so as to be able to maintain a free -OH, - Gln to Asn, so as to be able to maintain free NH2.

[0077] Amino acid substitutions can also be introduced to replace amino acids with particularly favorable properties. As an example, Cys can be introduced as a potential site for disulfide bridges with other Cys. His can be introduced as a particularly "catalytic" site (i.e., His can act as an acid or base and is the most common amino acid in biochemical catalysis). Pro can be introduced because of its particularly planar structure that induces a β-turn in the protein structure. Two amino acid sequences are "substantially homologous" when at least about 70% (preferably at least about 80%, most preferably at least about 90% or 95%) of the amino acid residues are identical or represent conservative substitutions.

[0078] Similarly, the nucleotide sequence used in the present invention can also be substituted, deleted, or inserted. If the codons encoding a particular amino acid are degenerate, any codon encoding the particular amino acid can be used. Furthermore, if it is desired to replace one amino acid with another, the nucleotide sequence can be modified according to the known genetic code.

[0079] Nucleotides and oligonucleotides can also be modified. U.S. Patent No. 7,807,816, which is incorporated by reference in its entirety, describes example modifications, particularly for the description of modified nucleotides and oligonucleotides.

[0080] Two nucleotide sequences are "substantially homologous" or "substantially identical" when at least about 70% (preferably, at least about 80%, and most preferably, at least about 90% or 95%) of the nucleotides are identical.

[0081] Two nucleotide sequences are "substantially complementary" when at least about 70% (preferably at least about 80%, and most preferably at least about 90% or 95%) of the nucleotides are capable of hydrogen bonding with a target sequence.

[0082] The term "standard hybridization conditions" refers to salt and temperature conditions substantially equivalent to 5xSSC and 60C for both hybridization and washing. However, one of skill in the art will understand that such "standard hybridization conditions" depend on the specific conditions, including the sodium and magnesium concentrations in the buffer, the length and concentration of the nucleotide sequence, the mismatch rate, and the formamide rate. Also important in determining "standard hybridization conditions" is whether the two hybridizing sequences are RNA-RNA, DNA-DNA, or RNA-DNA. Such standard hybridization conditions are conditions under which hybridization typically occurs at an expected or determined T, with higher stringency washing if desired. m10-20° C. lower, which can be easily determined by one skilled in the art according to well-known procedures.

[0083] The term "pharmaceutical acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not normally produce allergic or similar adverse reactions, such as stomach upset and dizziness, when administered to humans.

[0084] The term "therapeutically effective amount" is used herein to mean an amount sufficient to prevent, preferably reduce by at least about 30 percent, more preferably by at least 50 percent, and most preferably by at least 90 percent, clinically significant changes in cardiomyocyte characteristics.

[0085] The preparation of therapeutic compositions containing polypeptides, analogs, or active fragments as active ingredients is well understood in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions, although solid forms suitable for dissolving or suspending in liquid prior to injection can also be prepared. The preparations can also be emulsified. The active therapeutic ingredient is often mixed with an excipient that is pharma- ceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, or ethanol, and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance the effectiveness of the active ingredient.

[0086] Polypeptides, analogs, or active fragments, and small molecule inhibitors can be formulated into therapeutic compositions as pharma-ceutically acceptable neutral salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with free amino groups of the polypeptide or antibody molecule) formed with inorganic acids, such as, for example, hydrochloric or phosphoric acid, or organic acids, such as acetic, oxalic, tartaric, and mandelic acids. Salts formed from free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and organic bases, such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, and procaine.

[0087] The therapeutic compositions of the invention are conventionally administered intravenously, for example, by injection of a unit dose. The term "unit dose" when used in reference to the therapeutic compositions of the invention refers to physically discrete units suitable as unitary administration for human use, each unit containing a predetermined quantity of active material calculated to produce a desired therapeutic effect, together with the required diluent, i.e., carrier or vehicle.

[0088] The composition is administered in a therapeutically effective amount in a manner compatible with the dosage formulation. The amount administered will depend on the subject to be treated, the capacity of the subject's immune system to use the active ingredient, and the degree of inhibition of PP2A-mAKAPβ binding desired. The precise amount of active ingredient required for administration will depend on the judgment of the physician and will be specific to each individual. However, suitable dosages may range from about 0.1 to 20, preferably about 0.5 to about 10, and more preferably 1 to several milligrams of active ingredient per kilogram of the individual's body weight per day, depending on the route of administration. Also, suitable dosages for initial administration and booster injections may vary, but are typically an initial administration followed by subsequent readministration at intervals of one or more hours by subsequent injections or other administrations. Alternatively, continuous intravenous infusion sufficient to maintain a concentration of 10 nanomolar to 10 micromolar in the blood is contemplated.

[0089] Due to the need for the inhibitor to reach the cytosol, the peptide in the present invention may need to be modified to allow translocation in the cell membrane or may need to be expressed by a vector that codes for the peptide inhibitor. Similarly, nucleic acid inhibitors (including siRNA, shRNA, and antisense RNA) can be expressed by a vector. Any vector that can enter the targeted cell can be used in the present invention. In particular, viral vectors can "infect" cells and express the desired RNA or peptide. Any viral vector that can "infect" cells can be used. A particularly preferred viral vector is adeno-associated virus (AAV).

[0090] siRNAs inhibit the translation of target mRNAs through a process called RNA interference. When siRNAs are perfectly complementary to the target mRNA, they act by promoting mRNA degradation. shRNAs, as a special type of siRNA, have certain advantages over siRNAs in that they are made as oligonucleotides. siRNA oligonucleotides are typically synthesized in the laboratory and delivered to cells using a delivery system that delivers siRNA to the cytoplasm. In contrast, shRNAs are expressed as minigenes that are delivered to the cell nucleus by vectors, where shRNAs are transcribed and then processed into mature siRNA species by cellular enzymes such as Drosha and Dicer. siRNAs are typically 99% degraded after 48 hours, while shRNAs can be expressed for up to 3 years. Furthermore, shRNAs can be delivered at much lower copy numbers than siRNAs (5 copies vs. low nM), resulting in much less off-target effects, immune activation, inflammation, and toxicity. siRNAs are appropriate for acute disease conditions where high doses can be tolerated, whereas shRNAs are appropriate for chronic serious diseases or disorders where lower doses are desired (http: / / www.benitec.com / technology / sirna-vs-shrna).

[0091] Guidelines for designing siRNA and shRNA can be found in Elbashir (2001) and various websites including https: / / www.thermofisher.com / us / en / home / references / ambion-tech-support / rnai-sirna / general-articles / -sirna-design-guidelines.html and http: / / www.invivogen.com / review-sirna-shrna-design, all of which are incorporated herein by reference in their entirety. Preferably, the first nucleotide is A or G. siRNAs of 25-29 nucleotides are more effective than shorter ones, while longer shRNAs with a duplex length of 19-21 are also believed to be more effective. siRNAs and shRNAs are preferably 19-29 nucleotides. The loop sequence in the shRNA can be 3-9 nucleotides long, with 5, 7 or 9 nucleotides being preferred.

[0092] With respect to small molecule inhibitors, any small molecule that inhibits the interaction of PP2A and mAKAPβ can be used. Furthermore, any small molecule that inhibits the activity of PP2A and / or mAKAPβ can be used.

[0093] Small molecules of similar structure and function can similarly be determined by rational and screening approaches.

[0094] Similarly, any small molecule that inhibits the expression of PP2A and / or mAKAPβ can be used.

[0095] In further detail, the present invention is described by the following paragraphs setting forth preferred embodiments thereof. 1. A method for treating or preventing heart failure with reduced ejection fraction comprising administering to cardiac cells of a patient a composition that maintains phosphorylation levels in serum response factor (SRF). 2. SRF stands for Ser 103 The method according to item 1, wherein the gene is phosphorylated at 3. The method according to item 1, wherein the dephosphorylation activity of protein (serine-threonine) phosphatase 2A (PP2A) is inhibited. 4. The method according to item 3, which inhibits anchoring of PP2A to muscle A-kinase anchor protein (mAKAPβ). 5. The method according to paragraph 4, wherein the composition comprises a fragment of mAKAPβ. 6. The method of paragraph 5, wherein the composition comprises an amino acid sequence having at least 90% sequence identity to a fragment of mAKAPβ. 7. The method of claim 5, wherein the composition comprises a fragment of amino acids 2132 to 2319 of mAKAP. 8. The method according to item 5, wherein the composition comprises amino acids 2132 to 2319 of mAKAP. 9. The method according to paragraph 4, wherein the composition comprises a fragment of PP2A. 10. The method of paragraph 4, wherein the composition comprises a vector encoding a fragment of mAKAP. 11. The method of paragraph 4, wherein the composition comprises a vector encoding an amino acid sequence having at least 90% sequence identity to a fragment of mAKAP. 12. The method of claim 10, wherein the vector encodes a fragment of amino acids 2132 to 2319 of mAKAP. 13. The method of claim 10, wherein the vector encodes amino acids 2132 to 2319 of mAKAP. 14. The method of claim 10, wherein the vector is an adeno-associated virus (AAV). 15. A composition encoding a molecule that inhibits anchoring of PP2A to mAKAP. 16. The composition of paragraph 15, wherein the molecule comprises a fragment of mAKAP. 17. The composition according to item 15, comprising an amino acid sequence having at least 90% sequence identity with a fragment of mAKAP. 18. The composition according to item 16, comprising a fragment of amino acids 2132 to 2319 of mAKAP. 19. The composition according to item 16, comprising amino acids 2132 to 2319 of mAKAPβ. 20. The composition according to item 15, comprising a fragment of PP2A. 21. A composition comprising a vector encoding a molecule that inhibits anchoring of PP2A to mAKAP. 22. The composition of paragraph 21, wherein the vector encodes a fragment of mAKAP. 23. The composition of paragraph 21, wherein the vector encodes an amino acid sequence having at least 90% sequence identity to a fragment of mAKAP. 24. The composition of paragraph 21, wherein the vector encodes a fragment of amino acids 2132 to 2319 of mAKAP. 25. The composition of paragraph 21, wherein the vector encodes amino acids 2132 to 2319 of mAKAP. 26. The composition of paragraph 21, wherein the vector encodes a fragment of PP2A. 27. The composition of clause 21, wherein the vector is an adeno-associated virus (AAV).

[0096] The following examples are provided to aid in the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that variations can be made in the procedures set forth without departing from the spirit of the invention. EXAMPLES

[0097] The compositions and processes of the present invention will be more fully understood with reference to the following examples, which are intended to be illustrative only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Moreover, such changes and modifications can be made without departing from the spirit of the invention and the scope of the appended claims, including but not limited to, with respect to the processes, formulations and / or methods of the invention.

[0098] [Example 1] SRF regulation by the mAKAPβ signalosome Materials and Methods Culture of neonatal rat ventricular myocytes: Sprague-Dawley rats, 1-3 days old, were decapitated and the excised hearts were placed in 1x ADS buffer (116 mM NaCl, 20 mM HEPES, 1 mM NaH2PO4, 5.5 mM glucose, 5.4 mM KCl, 0.8 mM MgSO4, pH 7.35). The atria were carefully removed and blood was washed away. The ventricles were minced and incubated at 37°C in 15 mL of 1x ADS buffer containing 3.3 mg type II collagenase (Worthington, 230 U / mg) and 9 mg pancreatin (Sigma) with gentle shaking. After 15 min, disaggregated cardiomyocytes were isolated by centrifugation at 50 g for 1 min, resuspended in 4 mL horse serum, and incubated at 37°C with occasional mixing. To maximize yield, the steps of enzymatic digestion and isolation of myocytes were repeated 10-12 times. Myocytes were pooled, spun down again at 50g for 2 min, and resuspended in maintenance medium (DMEM:M199, 4:1) supplemented with 10% horse serum and 5% fetal bovine serum. To remove any contaminating fibroblasts, cells were pre-plated for 1 h before plating on gelatin-coated tissue culture plasticware. This procedure yielded cardiomyocytes with a purity of >90%. The next day after culture, the medium was changed to maintenance medium containing 0.1 mM bromodeoxyuridine to suppress fibroblast growth.

[0099] Isolation and culture of adult rat ventricular myocytes: Rats aged 2–3 months were anesthetized with ketamine (80–100 mg / kg) and xylazine (5–10 mg / kg) intraperitoneally after heparinization with 1000 U for cardiac excision. Hearts were immediately transferred into cold perfusion buffer (NaCl 120 mM, KCl 5.4 mM, Na2HPO4 7H2O 1.2 mM, NaHCO3 20.0 mM, MgCl2.6H2O 1.6 mM, taurine 5 mM, glucose 5.6 mM, 2,3-butanedione monoxime 10 mM) pre-equilibrated with 95% O2 and 5% CO2. After removal of extraneous tissue, hearts were attached via the aorta to a Harvard Langendorff apparatus cannula. Ca 2+Residual blood was flushed out using a Ca-free perfusion at a constant rate of 8-10 mL / min at 37°C. Hearts were then digested by cyclic perfusion with 50 mL perfusion buffer containing 125 mg type II collagenase (Worthington, 245 U / mg), 0.1 mg protease (Sigma type XIV) and 0.1% BSA. After perfusion, atria were removed and ventricular myocytes were sliced ​​and loosened by repeated pipetting. Cell debris was filtered through a 200 μm nylon mesh and myocytes were harvested by centrifugation at 50 g for 1 min. Ca in the buffer was removed. 2+ The concentration was gradually restored to 1.8 mM, and myocytes were resuspended in ACCT medium (M199 medium (Invitrogen 11150-059), supplemented with 5 mM creatine, 2 mM L-carnitine, 5 mM taurine, 25 mM HEPES, 10 mM 2,3-butanedione monoxime, 0.2% BSA, and 1× insulin-transferrin-selenium) and plated on dishes precoated with 10 μg / ml laminin. Cells were washed with ACCT medium 1.5 h after plating and subjected to adenovirus infection or siRNA transfection using 100 nmol / L siRNA mixed with adenovirus and Dharmafect1 (Dharmacon) at a multiplicity of infection (MOI) of 100–200, respectively. Adrenergic agents were added the next day, and biochemical assays and morphological measurements were performed 24 h after stimulation.

[0100] Other cell culture: HEK293 and COS-7 cells were maintained in DMEM containing 10% FBS and 1% P / S. The cells were transiently transfected with Lipofectamine2000 (Invitrogen) or infected with adenovirus and Adeno-X Tet-Off virus (Clontech) as suggested by the manufacturer.

[0101] Luciferase assay: 225,000 neonatal rat ventricular myocytes in 24-well dishes were transfected with control or RSK3-specific siRNA oligonucleotides (10 nM) and Dharmafect1 reagent (Thermofisher). The next day, cells were washed with medium, and then myocytes were retransfected with 100 ng SRE-luc (firefly luciferase) and 100 ng -36Prl-rluc (renilla luciferase) reporter plasmids and Transfast reagent for 1 h, then cultured overnight in medium containing 4% horse serum, washed with medium, and incubated with or without 10 μM PE for 1 day. Samples were collected in 100 μl PLB and assayed using the Promega Dual Luciferase Kit and Berthold Centro X luminometer.

[0102] Co-immunoprecipitation: Tissues were homogenized using a Polytron or cells were lysed in IP buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton-X 100, 1 mM DTT) containing an inhibitor cocktail (1 μg / ml leupeptin, 1 μg / ml pepstatin, 1 mM benzamidine, 1 mM AEBSF, 50 mM NaF, 1 mM sodium orthovanadate). Soluble proteins were isolated by centrifugation at 3-10,000 g for 10 min. Antibodies and protein-G agarose beads (50% slurry, Upstate) were added to the extracts and incubated overnight at 4°C with rocking. Beads were washed four times with IP buffer at 4°C. Bound proteins were size-fractionated on SDS-PAGE gels and developed by immunoblotting using a Fujifilm LAS-3000 or GE-AI600 imaging system as previously described (46). Protein markers were Precision Plus Protein Standards (Bio-Rad, 1610373).

[0103] Immunocytochemistry: Myocytes on coverslips were fixed in 3.7% formaldehyde in PBS for 1 h, permeabilized with 0.3% TritonX-100, and blocked in PBS containing 0.2% BSA and 1% horse serum. Slides were then incubated consecutively for 1 h with primary and Alexa fluorochrome-conjugated specific secondary antibodies (Invitrogen, 1:1000) diluted in blocking buffer. Slips were washed three times with blocking buffer. 1 μg / mL Hoechst 33258 was included in the final wash to stop nuclear labeling. Slides were mounted in SlowFade Gold antifade buffer (Invitrogen, S36938) for fluorescence microscopy. Widefield images were obtained using a Leica DM4000 microscope.

[0104] GST-SRF phosphorylation assay: GST-SRF protein was purified using BL21 E. coli and glutathione-Sepharose as previously described (Vargas et al. 2012). GST-SRF on beads was incubated with 0.5 μg of active recombinant full-length His6-tagged human RSK3 (Millipore 14-462) + / - 50 nM BI-D1870 in ATP-containing kinase buffer for 30 min. GST-SRF beads were then eluted with Laemmli buffer or washed with PP2A phosphatase buffer and incubated for an additional 30 min in the presence of 50 ng PP2A + / - 10 nM okadaic acid before elution with Laemmli buffer. Equal GST-SRF protein loading was measured by Ponceau staining and phosphorylation of SRF was measured as phospho-SRF S. 103 Detection was carried out using specific antibodies.

[0105] Plasmid constructs SRE-luciferase reporter - SRE-luc was generated by subcloning two copies of the c-fosSRF response element (TCGAC AGG ATG TCC ATA TTA GGA CAT CTG) (SEQ ID NO: ) (Treisman 1985) at the Xho I site upstream of the −36 bp rat prolactin promoter in a firefly luciferase reporter plasmid as previously described (Kapiloff et al. 1991).

[0106] -36Prl-Renilla luciferase - An oligonucleotide containing the rat prolactin promoter from -36 to +36 with BglII and HindIII affinity ends (GATCT CGA AGG TTT ATA AAG TCA ATG TCT GCA GAT GAG AAA GCA GTG GTT CTC TTA GGA CTT CTT GGG GAA GTG TGG TC) (SEQ ID NO: ) was subcloned into pRL-null (Promega) to obtain a control Renilla luciferase vector.

[0107] mAKAP fragment expression vector: The pS-EGFPC1-mAKAP-1694-1833-mh adenoviral shuttle vector was generated by subcloning the cDNA encoding the myc-, His6-, and GFP-tagged mAKAP aa 1694-1833 fragment (RBD) in pEGFPC1 (Clontech) (Li, Kritzer, et al. 2013) into the pTRE shuttle vector previously modified to contain the CMV immediate early promoter. pS-EGFPC1-mh is similarly designed, except for the deletion of the mAKAP sequence. The pTRE-myc-mAKAP PBD encoding the myc-tagged mAKAP aa 2134-2314 (PBD) fragment was generated by digesting and ligating pTRE-myc-mAKAP, which contains the full-length, N-terminally myc-tagged mAKAP cDNA, with Apa I-Sca I. pTRE-βgal, encoding the β-galactosidase control protein, was obtained from Clontech. The pAcTnTS-EGFP-mAKAP 1694-1833mh plasmid used to generate AAV-RBD was generated by subcloning the NheI-BamHI fragment of pEGFPC1-rmAKAP-1694-1833-mh (Li, Kritzer, et al. 2013) into pAcTnTs (Prasad et al. 2011), generously provided by Dr. Brent French, University of Virginia. The pAcTnTs-EGFP-mh plasmid for generating the AAV-GFP control virus was generated by digesting, blunting, and ligating pAcTnTS-EGFP-mAKAP 1694-1833mh with Acc65I and BsRGI. Other mAKAP plasmids were as previously described (Pare, Bauman, et al. 2005; Kapiloff, Jackson, and Airhart 2001).

[0108] SRF construct - pFlag-SRF, which expresses Flag-tagged SRF protein, was generated by subcloning human SRF cDNA from pCGN-SRF (Addgene plasmid #11977) into the XbaI / EcoRI sites of the pSH160c NFATc1 expression plasmid (Ho et al. 1995). pTRE-Flag-hSRF was generated by subcloning Flag-tagged SRF cDNA into the pTRE shuttle vector (Clontech). pTRE-3xHA-hSRF was generated by inserting a custom sequence within the SfiI and SanDI sites of pTRE-Flag-hSRF replacing the Flag tag with three tandem HA tags. The S103A and S103D mutations were introduced into the pTRE plasmid by site-directed mutagenesis to introduce the sequences ATCGCTGGCAGAG (SEQ ID NO: ) and GAGCCTGGATGAA (SEQ ID NO: ) instead of GAGCCTGAGCGAG (SEQ ID NO: ). pGEX-4T1-FLAG-hSRF for bacterial GST-SRF expression was generated by subcloning the NcoI (blunt-ended)-EcoRI fragment of pTRE-Flag-hSRF into the BamHI (blunt-ended)-EcoRI sites of pGEX-4T1.

[0109] RSK3 expression vector: Plasmids for HA-tagged RSK3 wild-type and S218A mutants and RSK3 fragments were as previously described (Li, Kritzer, et al. 2013). The pS-HA-hRSK3 1-42 adenoviral shuttle vector was generated by subcloning HA-tagged 1-42 cDNA into the BsaBI and NheI sites of pS-EGFPC1-mh, replacing the cDNA for tagged GFP.

[0110] Adenoviruses were prepared using the pTRE shuttle vector and the Adeno-X Tet-off system (Clontech) by PI-SceI and I-CeuI subcloning, and purified after amplification using the Vivapure AdenoPACK kit (Sartorius Stedim). These adenoviruses conditionally express recombinant proteins (adeno-tTA for "tet-off" or reverse tTA for "tet-on") when infected with a tetracycline transactivator expressing virus. Some adenoviruses were generated using a modified pTRE shuttle vector (pS) containing a constitutive CMV promoter.

[0111] result Given the role of RSK3 and mAKAPβ in determining concentric myocyte growth, the focus of research was on identifying RSK3 cardiomyocyte substrates. The transcription factor serum response factor (SRF) plays an important role in both cardiac development and adult function by regulating genes involved in growth and the actin cytoskeleton (Miano 2010). SRF contains the Ser 103 SRF undergoes multiple post-translational modifications (Figure 1), including phosphorylation (Mack 2011). Due to the prominent role of SRF in muscle cell regulation and previously demonstrated phosphorylation of SRF by other RSK family members (Miano 2010; Rivera et al. 1993; Janknecht et al. 1992; Hanlon, Sturgill, and Sealy 2001), SRF is thought to be an effector of RSK3 in cardiomyocytes. 103Phosphorylation of was readily confirmed using purified glutathione-S-transferase (GST)-SRF fusion protein (data not shown). SRF contains a conserved MADS (MCM1, agamous, deficiens, SRF) domain that mediates both DNA binding to CArG box [CC(A / T)6GG] serum response elements (SREs) and homo- or heterodimerization with other transcription factors (Figure 19A). Using RSK3 small interfering nucleotides (siRNAs) to deplete SRF from primary neonatal rat ventricular myocyte cultures (NRVMs) by RNA interference (RNAi), we determined that deletion of RSK3 inhibited SRE-dependent transient reporter activity, including that induced by the α-adrenergic agonist phenylephrine (PE, Figure 19B). Given that RSK3 binds the scaffold protein mAKAPβ (Li, Kritzer, et al. 2013), we tested whether SRF also associates with the mAKAPβ signalosome and promotes its phosphorylation. Endogenous mAKAPβ was stably co-immunoprecipitated with SRF in adult mouse heart extracts using an SRF antibody (Figure 19C). Moreover, when expressed in heterologous cells, SRF and RSK3 could associate in the presence of mAKAPβ to form a ternary complex (Figure 19D). Thus, inhibition of RSK3 and mAKAPβ expression in NRVMs abrogated PE-induced SRF phosphorylation at the Ser 103 mAKAPβ-RSK3 phosphorylation was inhibited (Figure 19E). Isoform-specific N-terminal RSK3 domains bind distinct "RSK3-binding domains" within mAKAPβ at residues 1694-1833 (RBD) (Li, Kritzer, et al. 2013). Expression of myc-tagged green fluorescent protein (GFP) RBD fusion proteins capable of competing with mAKAPβ-RSK3 binding (Li, Kritzer, et al. 2013) inhibited PE-induced SRF phosphorylation at Ser in both NRVMs and primary cultures of adult rat ventricular myocytes (ARVMs, Figure 19 and data not shown). 103 Similar results were obtained by inhibition of anchoring using the N-terminal RSK3 peptide (data not shown). These results were confirmed in vivo. 103Phosphorylation was reduced in hearts from both previously described RSK3 systemic and mAKAPβ myocyte-specific conditional knockout mice (Kritzer et al. 2014; Li, Kritzer, et al. 2013), as well as in RBD-expressing mice in vivo (data not shown). Together, these results reveal that SRF is an RSK3 substrate in myocytes that determines its phosphorylation in response to catecholamine stimulation through its association with the mAKAPβ signalosome.

[0112] mAKAPβ is a Ca 2+ It binds two phosphatases: the calmodulin-dependent phosphatase calcineurin (PP2B, PPP3) and the protein kinase A (PKA)-active isoenzyme of PP2A that contains the B56δ subunit (Dodge-Kafka et al. 2010; Li et al. 2010). Treatment of NRVMs with the PP1 / PP2A inhibitor okadaic acid (OA), but not the calcineurin inhibitor cyclosporine A (CsA), reduced baseline SRF Ser2 expression. 103 Thus, purified PP2A promoted phosphorylation of SRF at Ser 2+ . 103 PP2A readily dephosphorylated SRF (Fig. S1C). Like RSK3, SRF, PP2A, and mAKAPβ formed a ternary complex in NRVMs, since SRF and PP2A could only be coimmunoprecipitated in the presence of mAKAPβ (Fig. S1C). PP2A binds the C-terminal domain of mAKAPβ (Dodge-Kafka et al. 2010), and expression of the PP2A-binding domain (myc-PBD, Fig. 4) competed with endogenous mAKAPβ-PP2A association in myocytes (Fig. S1C). Consistent with previously published findings that cAMP activates mAKAPβ-bound PP2A (Dodge-Kafka et al. 2010), PBD expression inhibited the Ser-binding domain of SRF in ARVMs stimulated with β-adrenergic isoproterenol (Iso, Fig. S1C). 103Collectively, these results suggest that the mAKAPβ signalosome bidirectionally mediates the induction of SRF phosphorylation in response to various upstream stimuli. 103 It is shown that phosphorylation can be regulated.

[0113] [Example 2] SRF Ser 103 Phosphorylation promotes concentric hypertrophy While both neonatal rat ventricular myocytes (NRVMs) and adult rat ventricular myocytes (ARVMs) are useful for studying molecular signaling pathways involving α- and β-adrenergic-induced hypertrophy, the two cell samples differ significantly in shape, ultrastructure, and in some cases, cellular regulation (Peter, Bjerke, and Leinwand 2016). Taking advantage of their roughly cylindrical shape, ARVMs have been developed as an in vitro model for morphological hypertrophy that is more relevant to in vivo cardiac remodeling. Characterization of RSK3 knockout mice suggested that RSK3 is important for concentric hypertrophy (Passariello et al. 2016; Li, Kritzer, et al. 2013). High expression of RSK3 selectively increased the width of cultured ARVMs and significantly reduced the length / width ratio (Figure 20A,B). The results were similar to those obtained after 1 day of myocyte culture in the presence of phenylephrine (PE, Fig. 20C,D). PE induced an 8-10% increase in width and an 8-14% decrease in length / width ratio at 24 h, which compares favorably with the 17-21% increase in width and 14-21% decrease in length / width ratio of mouse myocytes in vivo 2 weeks after aortic coarctation (8,16). Notably, expression of the SRF S103D phosphorylation mimicking mutant also increased ARVM width and induced concentric hypertrophy to the same extent as PE treatment. However, expression of the SRF S103A mutant did not affect basal myocyte size but inhibited PE-induced concentric hypertrophy (Fig. 20E,F). This result is consistent with the SRF Ser-dependent increase in width and 14-21% decrease in length / width ratio at 24 h. 103This was phenocopied by expression of the RBD RSK3 anchoring disruptor peptide, which inhibits PE phosphorylation (Fig. 19F) (Fig. 20G,H). In contrast to PE and high RSK3 expression, chronic stimulation with the β-adrenergic agonist Iso increased both ARVM length and width, resulting in more symmetric hypertrophy (Fig. 20I,J), similar to the effects of chronic Iso infusion in vivo (Li, Kritzer, et al. 2013). Removal of PP2A phosphatase from the mAKAPβ signalosome, as did RBD and SRF S103A expression, had no effect on basal ARVM morphology. Moreover, as did SRF S103D expression, PBD anchoring disruptor expression did not enhance or attenuate PE-induced hypertrophy. In contrast, in the presence of Iso, PDB expression promoted centripetal hypertrophy of ARVMs, and Iso-induced increases in ARVM width and length tended to be greater and smaller, respectively, with the exception of PP2A. This latter result was consistent with the Iso-induced Ser-dependent increase in SRF. 103 These results were consistent with the PDB-dependent enhancement of phosphorylation of SRF (Fig. 19J). Together, these results suggest that mAKAPβ anchoring RSK3 and PP2A mediate the Ser phosphorylation of SRF to promote concentric cardiomyocyte hypertrophy. 103 This supports a model for regulating phosphorylation.

[0114] [Example 3] Regulation of PDE4D3 by mAKAPβ-bound PP2A Antibody - The following primary antibodies were used for immunoblotting: mouse monoclonal anti-GFP (Santa Cruz; 1:500), mouse monoclonal anti-VSV tag (Sigma: 1:1000), mouse monoclonal anti-mAKAP (Covance, 1:1000), 9E10 mouse anti-myc (Santa Cruz, Inc, 1:500 dilution), polyclonal anti-PP2A-C (Santa Cruz, 1:500), and polyclonal anti-PP1 catalytic subunit (Santa Cruz, Inc, 1:500). Phospho-specific antibodies for phospho-PDE4D3 Ser-54 were generated and affinity purified using phosphorylated and nonphosphorylated human PDE4D3 peptides containing residues 70-81 (21st Century Biochemicals) and used at a dilution of 1:500. Both non-phosphospecific and phospho-Ser-566 specific polyclonal B56δ antibodies were as previously described (Ahn et al. 2007).

[0115] Expression construct - Expression vectors for Flag-tagged B56δ, glutathione-S-transferase (GST) PP2A-A fusion proteins, and myc- and green fluorescent protein (GFP)-tagged rat and human mAKAP were as previously described (Ahn et al. 2007; Pare, Bauman, et al. 2005; Kapiloff et al. 1999a; Kapiloff, Jackson, and Airhart 2001). Myc-tagged mAKAP constructs defective for PP2A binding were generated by subcloning a PCR-generated cDNA fragment encoding rat mAKAP1286-2083 into pCMV-Myc (Clontech). mAKAPα and mAKAPβ are two alternatively spliced ​​isoforms of mAKAP expressed in the heart and brain, respectively (Michel et al. 2005b). mAKAPβ is identical to mAKAPα residues 245-2314, and all recombinant mAKAP proteins shown herein are based on mAKAPα. The expression vector used for PDE4D3 herein was generated by subcloning a cDNA encoding VSV-tagged PDE4D3 (Dodge et al. 2001) into a GFP expression vector (Clontech) to obtain a dual-tagged PDE4D3 protein.

[0116] Immunoprecipitation - HEK293 cells were used in this study as a heterologous system lacking mAKAP that can readily express a variety of wild-type and mutant proteins. Cells grown in 60 mm plates were transfected at 50%-70% confluency by the calcium phosphate method using 6 μg of each DNA construct per plate. Cells were harvested 24 h after transfection in 0.5 ml of HSE buffer (HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% TritonX-100 and protease inhibitors). Supernatants were incubated with 3 μg of antibody and 15 μl of prewashed protein A or G agarose beads. After overnight incubation at 4°C, immunoprecipitates were washed three times with the same buffer. Bound proteins were analyzed by immunoblotting.

[0117] For immunoprecipitation of endogenous native mAKAP complexes, adult rat hearts (Pel-Freeze) were homogenized in 10 ml of HSE buffer. After centrifugation at 15,000 × g for 25 min, the clarified extracts were immunoprecipitated as described above.

[0118] PDE Assay - PDE activity associated with immunoprecipitated protein complexes was assayed according to the method described by Beavo et al. (Beavo, Bechtel, and Krebs 1974). Samples were diluted with 45 μl of PDE buffer A (100 mM MOPS, pH 7.5, 4 mM EGTA, 1.0 mg / ml bovine serum albumin) and 50 μl of PDE buffer B [100 mM MOPS, pH 7.5, 75 mM MgAc, 1 μM cAMP, and 100,000 cpm[ 3 H]cAMP (Dupont, NEN)]. Inhibitors were included as indicated.

[0119] Phosphatase Assay - Phosphatase activity as a substrate 32Histones were measured using P-labeled histones according to the method of Ahn et al. (Ahn et al. 2007). Histones were incubated in 250 mM MOPS, pH 7.4, 2.5 mM MgAc, 100 mM β-mercaptoethanol, purified PKA catalytic subunit, 1 μM ATP, 20 μM histones, and 1 mCi [γ- 32 Radiolabeling was performed in reactions containing [P]ATP (6000 Ci / mmol). The reaction was stopped by the addition of 50% TCA and [ 32 P]histones were purified from free radioactive nucleotides by centrifugation. 32 The [P]histone pellet was washed once with 1 ml ether / ethanol / HCL (4:1:0.1) and three times with 1 ml ether / ethanol (4:1). The substrate was then suspended in 200 μl PP2A assay buffer (25 mM Tris, pH 7.4, 1 mM DTT, and 10 mM MgCl2) and precipitated with 50% TCA. After repeated washing, [ 32 P]histones were suspended in 200 μl of PP2A buffer.

[0120] To measure phosphatase activity, the immunoprecipitated protein complexes were washed twice in HSE buffer and once in PP2A reaction buffer. Immunoprecipitates were incubated with 100,000 cpm [ 32 P] histones in 20 μl of PP2A assay buffer for 30 min at 30°C. PP2A inhibitor (Calbiochem) was used at a concentration of 30 nM. Purified I-1 was used as a specific PP1 inhibitor after phosphorylation with PKA. The reaction was stopped by the addition of 100 μl of 20% TCA, followed by centrifugation for 10 min. Released 32 The TCA supernatant containing PO4 was measured by scintillation counting.

[0121] GST Pulldown - Glutathione resin adsorbed with PP2A-A subunit GST fusion protein or GST control protein was incubated with HEK293 cell extracts. After overnight incubation, the beads were washed three times. Bound proteins were analyzed by immunoblotting.

[0122] Statistics - Each "n" refers to a completely independent experiment performed using separate cultures or heart samples. All p values ​​were calculated using Student's t-test.

[0123] result Regulation of mAKAP-bound PDE4D3 by okadaic acid-sensitive phosphatase A negative feedback loop inherent to the mAKAP complex involving cAMP activation of PKA, PKA phosphorylation and activation of PDE4D3, and PDE4D3-catalyzed cAMP degradation has been previously described (Dodge et al. 2001). PDE4D3 phosphorylation was dependent on PKA binding to mAKAP. In contrast, mAKAP-associated phosphatases can be responsible for PDE4D3 dephosphorylation. PP2A and Ca 2+Both the calcineurin / calmodulin-dependent protein phosphatase (PP2B) associate with the mAKAP scaffold in cardiomyocytes (Pare, Bauman, et al. 2005; Kapiloff, Jackson, and Airhart 2001; Li et al. 2009). To begin this study, we used a heterologous system to test whether PP2A or PP2B could dephosphorylate PDE4D3 at Ser-54, a residue within a conserved region upstream of PDE4D3 that is required for PKA activation (Sette and Conti 1996). HEK293 cells, which overexpress mAKAP and PDE4D3, were treated with 300 μM okadaic acid (OA) to inhibit PP2A (and protein phosphatase 1 [PP1]) activity, or with 500 μM cyclosporine A (CsA) to inhibit PP2B activity (Figure 8A). After immunoprecipitation of the protein complex using mAKAP-specific antibodies, phosphorylation of PDE4D3 was assayed by immunoblotting with a phospho-specific antibody against residue Ser-54. OA treatment increased baseline PDE4D3 Ser-54 phosphorylation, whereas inhibition of PP2B had no effect (Fig. 8A, top panel, second row). This increase in phosphorylation was further enhanced by 1.8-fold when PKA was activated by addition of the adenylyl cyclase agonist forskolin (Fsk, Fig. 8A, top panel, fifth row). Notably, forskolin alone had no significant effect without phosphatase inhibition (Fig. 8A, fourth row). Immunoblotting using a non-phospho-specific antibody against PDE4D3 and an antibody against mAKAP showed that the two proteins were precipitated similarly under each condition (Fig. 8A, bottom panel).

[0124] Since phosphorylation of Ser-54 in PDE4D3 increases phosphodiesterase activity by 2-fold (Sette and Conti 1996), we tested whether OA treatment could also increase mAKAP-bound PDE4D3 activity. mAKAP complexes were immunoprecipitated from transfected HEK293 cells and assayed for associated phosphodiesterase activity (Fig. 8B). mAKAP-associated phosphodiesterase activity in untreated cells was only detected when mAKAP was coexpressed with PDE4D3 (Fig. 8B, bar 1, and data not shown), consistent with previous findings that PDE4D3 represents all of the phosphodiesterase activity associated with mAKAP in cardiomyocytes (Dodge et al. 2001). Consistent with the results obtained with the phospho-Ser-54 antibody, Fsk treatment alone was not sufficient to stimulate mAKAP-bound PDE4D3 activity in HEK293 cells, whereas Fsk and OA treatment together synergistically enhanced PDE4D3 activity (Fig. 8B, bars 3 and 6). CsA had no effect on either basal or stimulated PDE4D3 activity, suggesting that PP2B does not regulate mAKAP-bound PDE4D3 in cells under these conditions. These results together indicate that in this heterologous system, OA-sensitive phosphatases potently inhibit both baseline and Fsk-stimulated phosphorylation and activity of mAKAP-bound PDE4D3.

[0125] The enhancement of phosphodiesterase activity by OA was seen not only in the expression of recombinant protein in HEK293 cells, but also in the isolation of native mAKAP complex from adult rat heart extracts (Fig. 8C). Both PDE4D3 and PKA are active in the purified mAKAP complex (Dodge et al. 2001). PKA activity present in the endogenous mAKAP complex accounts for a two-fold increase in phosphodiesterase activity, as was evident upon inhibition of mAKAP-bound PKA by the specific PKA inhibitor PKI (Fig. 8C, bars 2 and 4). Importantly, OA inhibition increased mAKAP-associated phosphodiesterase activity by 30% (bars 2 and 3) and by 60% (bars 4 and 5) when PKA was also inhibited. Together, these data indicate that OA-sensitive phosphatases associated with the mAKAP complex are responsible for the dephosphorylation of PDE4D3 and the regulation of phosphodiesterase activity.

[0126] PP2A associates with the mAKAP scaffold in the heart. Having observed that the OA-sensitive phosphatase was associated with the mAKAP complex, the phosphatase was identified by co-immunoprecipitation experiments. Phosphatase activity associated with the mAKAP complex isolated from cardiac cell extracts was detected using [ 32 Phosphatase activity was measured using [P] histone over control IgG immunoprecipitates, resulting in a threefold increase in phosphatase activity (Fig. 9A, bars 1 and 2). The mAKAP-associated phosphatase responsible for the immunoprecipitated activity was identified as PP2A, because phosphatase activity was completely inhibited by 30 nM PP2A inhibitor I (Li, Makkinje, and Damuni 1996) but not by the addition of 100 nM PKA phosphorylation PP1 inhibitor-1 (Endo et al. 1996). As a positive control, PKA phosphorylation PP1 inhibitor-1 did indeed inhibit PP1 isolated by immunoprecipitation with PP1 antibody from HEK293 cell extracts (Fig. S16). The mAKAP-associated phosphatase activity was not due to mAKAP-bound PP2B, which is thought to be due to Ca 2+This was because calmodulin was not included in the phosphatase assay buffer. Corroboration of these results was obtained by immunoblotting analysis of mAKAP immunoprecipitates. The PP2A-C subunits, but not the PP1 catalytic subunit, were detected in mAKAP-specific immunoprecipitates (Figures 18B and C).

[0127] Like PKA, PP2A associates with many cellular substrates and is predicted to reside in multiple subcellular compartments (Virshup 2000). Confocal fluorescence microscopy of cultured primary neonatal rat cardiomyocytes revealed that the PP2A-C subunit was distributed throughout the cytoplasm in a fine punctuate pattern (Figure 17, green). As previously found, mAKAP was localized primarily to the nuclear envelope (Pare, Easlick, et al. 2005). Consistent with coimmunoprecipitation of mAKAP and PP2A from adult rat heart extracts, overlapping PP2A and mAKAP staining could be detected at the nuclear envelope (Figure 17, composite image), supporting the model that a localized signaling complex consisting of PP2A, PKA, and PDE4D3, as well as distinct pools of the scaffold mAKAP, exists in cardiomyocytes.

[0128] mAKAP residues 2083-2319 contain the PP2A binding domain. To map the PP2A-binding site in mAKAP, bacterially expressed PP2A-A subunit GST fusion proteins were used to pull down GFP-tagged fragments of mAKAP expressed in HEK293 cells (Figure 10A and B). GST-PP2A-A stably pulled down only the fragment of mAKAP containing the domain from the C-terminus to residue 2085. GFP fusion proteins of human and rat mAKAP, including rat mAKAP 1835-2312 and human 2085-2319, bound GST-PP2A-A. As a negative control, GFP-mAKAP fusion proteins did not bind PP1 in HEK293 cells, consistent with the lack of coimmunoprecipitation of PP1 and mAKAP from cardiac extracts (Figure 18). To confirm the mapping of the PP2A-binding site in mAKAP, myc-tagged mAKAP fragments expressed in HEK293 cells were immunoprecipitated with myc-tagged antibodies and assayed for associated PP2A activity (Fig. S10C). Segment 1286-2312 of mAKAP, but not segment 1286-2083 of mAKAP, coimmunoprecipitated with OA-sensitive phosphatase activity. These data together indicate that PP2A binds a C-terminal site within mAKAP that is distant from the binding sites of PKA, PDE4D3, and other known mAKAP-binding proteins (Fig. S10A).

[0129] mAKAP-anchoring PP2A in the complex regulates PDE4D3 phosphorylation. Data obtained using mAKAP complexes isolated from rat heart extracts suggested that mAKAP-bound PP2A regulates PDE4D3 in a complex (Figure 8C). To test whether PP2A anchoring is required for PDE4D3 dephosphorylation, PDE4D3 was expressed in HEK293 cells and a mAKAP construct containing binding sites for PDE4D3, PKA, and PP2A (myc-mAKAP 1286-2312) or a similar mAKAP construct without the PP2A binding site (myc-mAKAP 1286-2083) was expressed. Cells were stimulated with Fsk and OA, and mAKAP complexes were subsequently isolated by immunoprecipitation. Phosphorylation of mAKAP-bound PDE4D3 was assayed by immunoblotting with a Ser-54 phosphospecific antibody. As seen upon expression of full-length mAKAP (Fig. 8A), we detected phosphorylation of PDE4D3 bound to myc-mAKAP1286-2312 only when phosphatase activity was suppressed by OA (Fig. 11A, column 3). Notably, upon expression of myc-mAKAP1286-2083 without significant PP2A binding (Fig. 11A, columns 4-6), we detected an increase in baseline mAKAP-bound PDE4D3 phosphorylation (0.49 ± 0.19-fold of the level obtained with OA, Fig. 11A, column 4 vs. column 3). Furthermore, upon deletion of the PP2A-binding domain, Fsk alone increased phosphodiesterase phosphorylation to levels equivalent to those associated with PP2A-containing complexes treated with both Fsk and OA (Fig. 11A, columns 3, 5, and 6). The change in PDE4D3 Ser-54 phosphorylation was reflected by the change in phosphodiesterase activity (FIG. 11B). PDE4D3 activity was 30% higher in myc-mAKAP1286-2083 immunoprecipitates without PP2A than in complexes containing phosphatases (bars 1 and 4). Importantly, no significant difference in PDE4D3 activity was observed between Fsk stimulation in complexes without PP2A and Fsk stimulation in the presence of OA (bars 5 and 6). These data indicate the importance of PP2A anchoring in regulating PDE4D3 phosphorylation and activity.Furthermore, they show that PP2A not only suppresses PKA-activated phosphodiesterase activity, but also functions to maintain low basal levels of PDE4D3 activity in unstimulated cells.

[0130] The mAKAP-binding PP2A holoenzyme containing the B56δ subunit is regulated by PKA. The PP2A holoenzyme is composed of three subunits, including a heterodimer of core A and C subunits and a B subunit that may target the holoenzyme to specific subcellular organelles (Virshup 2000). Three closely related B subunits, B56δ, B56γ1, and B56γ3, have been identified that are expressed in the heart and localized to the nucleus (Gigena et al. 2005; McCright et al. 1996). Recent studies have shown that the B56δ-containing PP2A holoenzyme is regulated by PKA phosphorylation (Ahn et al. 2007). We tested whether PP2A associated with the mAKAP complex could also be regulated by PKA activity. Native mAKAP complexes were immunoprecipitated from adult rat heart extracts and assayed for associated phosphatase activity (Figure 12A). mAKAP-associated phosphatase activity was increased 2.5-fold by stimulation of bound PKA with the nonhydrolyzable cAMP analog CPT-cAMP (columns 2 and 3). As controls, all immunoprecipitated phosphatase activity was inhibited by 10 mM OA (column 4), and the CPT-cAMP-stimulated increase in phosphatase activity was blocked by addition of the PKA inhibitor PKI (column 5). Together, these data indicate that PP2A activity associated with the mAKAP complex in the heart is enhanced by PKA-dependent cAMP signaling.

[0131] Since mAKAP-bound PP2A is regulated by PKA activity, we tested whether the mAKAP-bound PP2A holoenzyme contains the B56δ subunit. Protein complexes were immunoprecipitated from adult rat heart extracts using B56δ and control (IgG) antibodies (Fig. S12B). mAKAP was stably immunoprecipitated with the B56δ antibody. Moreover, we expressed Flag-tagged B56δ in HEK293 cells and showed that B56δ was immunoprecipitated with the mAKAP antibody only when it was coexpressed with (GFP-tagged) mAKAP (Fig. S12C). Finally, we showed that the binding of B56δ to mAKAP recruited the PP2A-C subunit to the complex, since mAKAP complexes immunoprecipitated from HEK293 cell extracts were associated with greater phosphatase activity when GFP-mAKAP was coexpressed with Flag-B56δ (Fig. S12D, lanes 2 and 3). Based on these results, B56δ recruits PP2A-A / C core heterodimers to the mAKAP complex in the heart, conferring cAMP-dependent phosphatase activity. Accordingly, elevation of intracellular cAMP by Fsk and the phosphodiesterase inhibitor IBMX increased mAKAP-associated phosphatase activity in HEK293 cells only when mAKAP was coexpressed with B56δ (Figure S4E).

[0132] PKA binding is required for cAMP-dependent PP2A activity in the mAKAP complex. Previous studies have found that PKA phosphorylates B56δ at four serine residues (53, 68, 81, and 566), suggesting that Ser-566 corresponds to induction of PP2A activity (Ahn et al. 2007). Because the mAKAP complex contains both PKA and PP2A, the association of these molecules into the complex was found to be important for PP2A phosphorylation, as PP2A binding to mAKAP is required for PDE4D3 dephosphorylation (Figure 11). To test this hypothesis, B56δ was expressed in HEK293 cells together with wild-type full-length mAKAP or a full-length mAKAP mutant with an internal deletion of residues 2053-2073 (ΔPKA, Figure 13A), which contains the PKA binding site (Pare, Bauman, et al. 2005). After stimulating cells with Fsk / IBMX to elevate intracellular cAMP, mAKAP complexes were isolated by immunoprecipitation and the phosphorylation status of B56δ was measured using a phospho-specific antibody against Ser-566 of B56δ (Fig. 13A, top panel) (Ahn et al. 2007). Phosphorylation of B56δ was detected only after FSK / IBMX treatment and only when B56δ was co-expressed with wild-type mAKAP but not with the ΔPKA mutant (Fig. 13A, rows 2 and 6). As a control, comparable expression of mutant and wild-type mAKAP and B56δ proteins was shown by immunoblotting with non-phospho-specific antibodies (Fig. 13A, middle and bottom panels). Furthermore, wild-type mAKAP was co-expressed with a mutant form of B56δ that contains an alanine residue at each of the four PKA substrate sites (S4A). As expected, Fsk / IBMX stimulation did not induce phosphorylation of S4A of B56δ (FIG. 13A, lane 4). Because phosphorylation of B56δ increases PP2A catalytic activity, mAKAP antibody immunoprecipitates were assayed for phosphatase activity (FIG. 13B). Consistent with the results obtained using the phospho-specific B56δ antibody, elevated cAMP increased phosphatase activity in mAKAP complexes by 1.7-fold (FIG. 13B, lanes 2 and 3). This increase required phosphorylation of B56δ, since complexes containing S4A mutants did not show an expansion of PP2A activity with increased cAMP (lane 5).Similarly, PKA binding to mAKAP was required to induce PP2A activity, since no increase was obtained when B56δ was coexpressed with the ΔPKA mutant scaffold of mAKAP (column 6). Interestingly, the Fsk / IBMX-induced increase in mAKAP-associated PP2A activity was not due to increased PP2A-C subunit binding to the mAKAP complex (Figure S13A, columns 1 and 2). This result is consistent with previous suggestions that phosphorylation of B56δ increases PP2A catalytic activity through a conformational change that does not affect holoenzyme formation (Ahn et al. 2007).

[0133] PP2A regulates PDE4D3 phosphorylation in a PKA-dependent manner. The above results suggest that PP2A dephosphorylation of PDE4D3 in B56δ-mAKAP complexes should be enhanced by PKA-catalyzed phosphorylation of the phosphatase. To identify the role of B56δ phosphorylation in the regulation of PDE4D3, PDE4D3 and mAKAP were coexpressed with either wild-type B56δ or the B56δ S4A mutant, which is unresponsive to PKA. Cells were stimulated with Fsk and then mAKAP complexes were isolated. As detected by immunoblotting with phospho-specific antibodies and enzyme assays, Fsk stimulation of PDE4D3 Ser-54 phosphorylation and phosphodiesterase activity was observed only in mAKAP complexes containing wild-type B56δ when PP2A was inhibited by OA (Figure 14A and B, 1-3), consistent with the data previously described (Figure 8). On the other hand, expression of B56δ S4A led to detectable Fsk-stimulated PDE4D3 phosphorylation (0.39±0.15-fold over Fsk / OA-stimulated cells; Fig. 4A, column 5) and a concomitant increase in phosphodiesterase activity (Fig. 14B, column 5), but not as potent as direct inhibition of PP2A activity by OA (Fig. 14A and B, columns 3 and 6). Together with the results shown in Figs. 12 and 13, anchoring of PKA-stimulated PP2A holoenzyme accounts for the suppression of both basal and PKA-stimulated PDE4D3 activity in the mAKAP signaling complex.

[0134] Consider The results described herein define a biochemical mechanism for the dephosphorylation and inactivation of PKA-phosphorylated PDE4D3 bound by the scaffold protein mAKAP. The PP2A heterotrimer, composed of A, C, and B56δ subunits, binds a C-terminal site on mAKAP that is distinct from the binding sites of other known mAKAP partners (Figure 10). The association of PP2A with the mAKAP scaffold has two important and novel functional implications. First, mAKAP binds both PP2A and PDE4D3, trapping the phosphatase in close proximity to the phosphodiesterase, allowing for effective PDE4D3 dephosphorylation and downregulation (Figure 11). Second, mAKAP binds both PKA and PP2A, promoting cAMP-dependent phosphorylation of the B56δ subunit of PP2A and induction of PP2A activity (Figure 13). The involvement of multimolecular signaling complex formation was evident upon expression of a mAKAP mutant lacking the binding sites for PP2A and PKA.

[0135] The idea of ​​targeting phosphatases to obtain substrate specificity was first presented in the mid-1980s with the identification of glycogen particle-associated protein as the first PP1 target subunit (Bauman and Scott 2002). Since this early finding, several other phosphatase targeting motifs have been identified (Virshup 2000). AKAPs represent an important mechanism for linking phosphatases to their appropriate substrates, and several AKAPs bind protein phosphatases. It has recently been shown that mAKAP binds PP2B (calcineurin) and that this interaction is important for PP2B-dependent NFATc3 activation in muscle cells (Li et al. 2009). However, PP2B binding to mAKAP has not been found to regulate PDE4D3, since inhibition of PP2B did not affect Ser-54 phosphorylation or phosphodiesterase activity of PDE4D3 (Figure 8). The present data support a unique role for PP2A binding to mAKAP in the dephosphorylation of phosphodiesterases and, consequently, in regulating local cAMP levels.

[0136] The role of the overall phosphatase in regulating cellular cAMP concentrations has not yet been fully explored. In rat adipocytes, PP2A was found to regulate both PDE3B activity and phosphorylation (Resjo et al. 1999). In addition to being phosphorylated by PKA at Ser-54, PDE4D3 is phosphorylated at Ser-579 by MAP kinases, including ERK5, which are present in the mAKAP complex (Hoffmann et al. 1999; Dodge-Kafka et al. 2005). Although PP1 is not found to bind mAKAP (Figures 9 and 18), PP1 can dephosphorylate Ser-579 of PDE4D3 in other cellular domains, because addition of purified PP1 to isolated PDE4D3 reduces phosphorylation at this site. Phosphatases are also responsible for dephosphorylation of mAKAP-bound PDE4D3 at Ser-579 and at the second PKA site in PDE4D3, Ser-16 (Carlisle Michel et al. 2004).

[0137] The anchoring hypothesis suggests that AKAPs function to target the action of PKA on specific substrates by localizing both proteins in the same signaling complex. Herein, we present a new target for PKA in the mAKAP complex, the B56δ subunit of PP2A. Previous studies have found that phosphorylation of B56δ stimulates PP2A activity and enhances the dephosphorylation of DARPP-32 (Ahn et al. 2007). Consistent with these results, stimulating cardiomyocytes with β-adrenergic receptor agonists increases PP2A activity (De Arcangelis, Soto, and Xiang 2008). The mAKAP scaffold may facilitate this event, as the association of anchoring proteins to both PKA and PP2A is important for cAMP-induced increases in phosphatase activity (Figures 11 and 13). Thus, mAKAPs have a role in regulating phosphatase activity in the heart.

[0138] Based on these results, we present a model in which PP2A plays a dual role in regulating cAMP levels near the mAKAP signaling complex (Figure 15). First, PP2A in the mAKAP complex should maintain PDE4D3 in a dephosphorylated, minimally active state without GPCR stimulation (Figure 15A), presumably allowing cAMP levels to rise more rapidly in response to agonists. Second, after GPCR stimulation induces activation of cAMP levels, PKA can phosphorylate both PDE4D3 and PP2A (Figure 15B). In contrast to the negative feedback on cAMP levels mediated by increased PDE4D3 phosphorylation, PKA phosphorylation of PP2A opposes PDE4D3 activation. By inhibiting PDE4D3 phosphorylation, PP2A presumably enhances and prolongs the action of local cAMP as part of a positive feedback loop. Thus, together with the previously described potential inhibition of PDE4D3 by mAKAP-bound ERK5 (not shown) (Dodge-Kafka et al. 2005), the mAKAP signaling complex is poised to finely regulate local cAMP levels both through multiple feedback loops inherent to the complex and through crosstalk with upstream MAPK signaling pathways. It has been observed that PP2A expression and subcellular localization are altered in heart failure (Reiken et al. 2001; Ai and Pogwizd 2005). Whether PP2A-mediated positive feedback or PDE4D3-mediated negative feedback primarily regulates cAMP levels localized to the mAKAP complex may ultimately depend on both the stoichiometry of PP2A binding to mAKAP in pathology and the relative rates of PDE4D3 phosphorylation and dephosphorylation by PKA and PP2A.

[0139] This example shows a novel mechanism by which the scaffolding protein mAKAP maintains dynamic regulation of anchoring PDE4D3 activity through association with PDE4D3, PKA, and PP2A. Each of these three enzymes plays a key role in the temporal regulation of cAMP concentrations in the vicinity of the perinuclear mAKAP complex. This complex regulation of local cAMP by the mAKAP "signalosome" indicates a widespread role for AKAPs and phosphatases in regulating cAMP compartmentalization.

[0140] [Example 4] Use of PBDs as a treatment for HFrEF Heart failure, the common end stage of heart disease, is a syndrome of great public health importance, affecting 6.5 million Americans with 960,000 new cases annually (Benjamin et al. 2017). Patients with symptomatic heart failure can be divided almost equally between those with reduced ejection fraction (HFrEF) and those with preserved ejection fraction. First-line therapies for heart failure include angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic receptor blockers (β-blockers), which can improve survival and quality of life, and reduce mortality, at least in HFrEF (Ponikowski et al. 2016). However, despite these and other supportive therapies, 5-year mortality remains around 50% in heart failure (39% in a 2016 post-myocardial infarction study) (Benjamin et al. 2017; Gerber et al. 2016), necessitating the discovery of new therapeutic approaches. Phosphorylation of SRF represents a novel mechanism regulating the transition from compensatory hypertrophy to a dilated, failing heart in HFrEF.

[0141] As mentioned above, expression of SRF S103D both in vitro and in vivo can promote eccentric myocyte hypertrophy. Furthermore, expression of the PP2A anchoring disruptor PBD suppressed eccentric hypertrophy induced by Iso treatment in cultured adult myocytes (Figure 20). These results support the conclusion that SRF S 103These results suggest that phosphorylation of SRF promotes widthwise growth while inhibiting elongation of cardiomyocytes. Given these results and the association of SRF dephosphorylation with systolic dysfunction induced by chronic pressure overload (data not shown), restoration of normal or increased SRF phosphorylation may prevent the ventricular dilation that leads to HFrEF in chronic pressure overload and ischemic heart disease.

[0142] Mechanisms that induce "compensatory" concentric hypertrophy early in cardiac disease predispose the heart to later systolic dysfunction and eventual failure (Schiattarella and Hill 2015). In this regard, targeting the RSK3-mAKAPβ complex may prevent pressure overload-induced cardiac remodeling and prevent heart failure (Kritzer et al. 2014; Li, Kritzer, et al. 2013). Although inhibition of signaling pathways that induce remodeling, including concentric hypertrophy, may be desirable early in disease, the question remains whether efforts to maintain signals that promote concentric myocyte hypertrophy and inhibit eccentric myocyte hypertrophy could preserve cardiac volume and evoked contractility when the heart is at a stage in the disease process characterized by eccentric growth and ventricular enlargement that leads to HFrEF. Thus, maintaining SRF phosphorylation represents a way to inhibit the eccentric changes in ventricular morphology that characterize end-stage disease and HFrEF. Thus, maintaining SRF phosphorylation represents a strategy to prevent the eccentric changes in ventricular morphology that characterize end-stage disease and HFrEF, which is further supported by our new finding that SRF phosphorylation is increased in mice subjected to acute pressure overload and decreased in mice and humans undergoing ventricular dilation. 218As detected by phosphorylation, phosphorylated SRF increases by 28% in total left ventricular extracts (containing approximately one-third of myocytes by cell number) within 5 min after induction of pressure overload (Fig. 33A and B) when RSK3 activation increases 1.9-fold (Fig. 33C). Notably, 16 weeks after aortic coarctation surgery, when the hearts are dilated and the mice are in heart failure (Fig. 33D), phosphorylated SRF is 30% lower than that present in sham-operated controls (Fig. 33E). These results are consistent with a phosphatase responsible for dephosphorylating SRF upon induction of eccentric hypertrophy, as opposed to RSK3-catalyzed phosphorylation. The relevance of this finding to human disease was evaluated using patient tissue samples. SRF Ser in left ventricular tissue from patients with normal left ventricular internal diameters was significantly higher than that in the control group (Fig. 33D). 103 Compared with phosphorylation, SRF Ser in patients with dilated hearts 103 Phosphorylation was reduced by 53% (p=0.005, Figures 33F-H).

[0143] Improving ventricular geometry, i.e., reducing LV internal diameter with less elongated myocytes and / or increasing LV wall thickness with wider myocytes, may reduce wall stress (Laplace's law) and improve systolic function in HFrEF-prone hearts. Prevention of systolic dysfunction has been obtained in a new AVV gene therapy vector based on expression of mAKAPβ-derived PBD (Figure 22).

[0144] Treatment of myocardial infarction Coronary heart disease is a major contributing factor to HFrEF (Writing Group et al. 2016). Eight-week-old C57BL / 6WT mice underwent permanent LAD ligation or sham thoracotomy. Two days after surgery, cardiac function was assessed by echocardiography and mice were randomized by EF and body weight (Figure 23B). Two cohorts of mice treated with either AAVsc.myc-PBD (n=8) or AAVsc.GFP (n=5) were determined to have a mean ejection fraction=34% two days after LAD ligation (Figure 23D). Three days after surgery, mice were injected with 5x10 11vg was injected via the tail vein. Control GFP mice showed a progressive decline in ejection fraction (EF of 21%), whereas PBD mice showed a long-term recovery of systolic function (EF = 43% 8 weeks after surgery, p<0.0001). Furthermore, AAVsc.myc-PBD-treated mice showed reduced left ventricular volumes (systolic - 69 μl in PBD vs. 156 μl in GFP, p<0.001; diastolic - 118 μl vs. 192 μl, p<0.001), consistent with improved cardiac function. At the endpoint, gravimetric analysis showed reduced ventricular and atrial hypertrophy (p=0.053 and 0.024, respectively, correlated with tibia length, FIG. 23C), and pulmonary edema, a sign of heart failure, tended to improve (p=0.078). These results indicate that PP2A anchoring disruptor therapy, which removes PP2A from mAKAPβ, where PP2A can dephosphorylate SRF, constitutes a novel therapeutic approach to prevent heart failure with reduced ejection fraction in ischemic heart disease.

[0145] method A common method for ligating the left coronary artery Mice were anesthetized with 5% isoflurane for induction and then 2.5–3% isoflurane for maintenance. Oral endotracheal intubation was performed using a 16G catheter, after which the mice were mechanically ventilated using a minivent ventilator. The skin over the left thoracotomy site was pre-prepared and draped to be sterile using povidone-iodine 10% solution. A heating pad was used to keep the mice warm during the procedure to prevent heat loss. Surgical sterile non-medicated eye ointment was applied to the eyes before surgery to prevent corneal dryness. Surgery was performed under a microscope. Once adequate sedation was achieved, the chest was opened by a left thoracotomy at the fourth intercostal space. Hemostasis was achieved using a thermal cautery device (e.g., Finetip, Bovie) in case of muscle bleeding. A 3 mm retractor was used to separate the ribs. After pericardiotomy, the left coronary artery was ligated with a 7-0 prolene suture to obtain an anterior wall MI. The chest was closed in three layers with 5-0 absorbable sutures (muscle) and silk 6-0 (2 ligatures for ribs and skin). A single dose of 0.5-1 mg / kg buprenorphine sustained release (Bup-SR-LAB) was administered subcutaneously immediately after surgery to suppress pain for 72 hours. Fluid replacement was administered immediately after surgery (e.g., sterile saline 0.9%, intraperitoneally). Mice were allowed to recover until alert and active. Sham-operated mice, which underwent everything except coronary artery ligation, served as controls.

[0146] Echocardiography Mice were minimally anesthetized with 1-2% isoflurane and studied using a high-resolution imaging system, Vevo2100® (VisualSonics). M-mode images were obtained in anesthetized mice at various time points. The diastolic and systolic thickness of the posterior and anterior walls and the end-diastolic diameter (LVEDD) and end-systolic diameter (LVESD) of the left ventricular cavity were measured, and estimates of LV volumes, fractional shortening, and ejection fraction were performed.

[0147] The patent and scientific literature referenced herein represents the knowledge available to those skilled in the art. All U.S. patents and published or unpublished U.S. patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are incorporated by reference.

[0148] While the present invention has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention contained in the appended claims.

[0149] [References] Using siRNA for gene silencing is a rapidly evolving tool in molecular biology, ThermoFisher Scientific, retrieved June 16, 2017 <https: / / http: / / www.thermofisher.com / us / en / home / references / ambion-tech-support / rnai-sirna / general-articles / -sirna-design-guidelines.html> . Abrenica B, AlShaaban M, Czubryt MP. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy. J Mol Cell Cardiol 46: 674-681, 2009. Ahn JH, McAvoy T, Rakhilin SV, Nishi A, Greengard P, Nairn AC (2007) Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci USA 104:2979-2984. Ai X, Pogwizd SM (2005) Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ Res 96:54-63. Andino LM, Conlon TJ, Porvasnik SL, Boye SL, Hauswirth WW, Lewin AS (2007) Rapid, widespread transduction of the murine myocardium using self-complementary Adeno-associated virus. Genetic vaccines and therapy 5:13. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747-758. Appert-Collin A, Cotecchia S, Nenniger-Tosato M, Pedrazzini T, Diviani D. The A-kinase anchoring protein (AKAP)-Lbc-signaling complex mediates alpha1 adrenergic receptor-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 104: 10140-10145, 2007. Avkiran M, Cook AR, Cuello F. Targeting Na+ / H+ exchanger regula- tion for cardiac protection: a RSKy approach? Curr Opin Pharmacol. 2008;8:133-140. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007;408:297-315. Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, Kreusser MM, Sun Q, Chen L, Heft C, Katus HA, Olson EN (2011) Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol 195:403-415. Bauman AL, Scott JD (2002) Kinase- and phosphatase-anchoring proteins: harnessing the dynamic duo. Nat Cell Biol 4:E203-206. Bauman AL, Michel JJ, Henson E, Dodge-Kafka KL, Kapiloff MS, “The mAKAP signalosome and cardiac myocyte hypertrophy,” IUBMB Life. 2007 Mar;59(3):163-9. Review. Beavo JA, Bechtel PJ, Krebs EG (1974) Preparation of homogeneous cyclic AMP-dependent protein kinase(s) and its subunits from rabbit skeletal muscle. Methods Enzymol 38:299- 308. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 19: 192-198, 2007. Benjamin EJ et al. (2017) Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 135:e146-e603. Benjamin EJ et al. (2019) Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 139: e56-e528. Bers DM (2006) Cardiac ryanodine· receptor phosphorylation: target sites and functional consequences. Biochem J 396:el-3. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70: 23-49, 2008. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D (1994) Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet 8:323-327. Black BL, Olson EN (1998) Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14:167-196. Bonne G, Di Barletta MR, Vamous S, Becane HM, Hammouda EH, Merlini L, Muntoni F, Greenberg CR, Gary F, Urtizberea JA, Duboc D, Fardeau M, Toniolo D, Schwartz K (1999) Mutations in the gene encoding lamin NC cause autosomal dominant Emery- Dreifuss muscular dystrophy. Nat Genet 21:285-288. Bourajjaj M, Armand AS, da Costa Martins PA, Weijts B, van der Nagel R, Heeneman S, Wehrens XH, De Windt LJ (2008) NFATc2 is a necessary mediator of calcineurin- dependent cardiac hypertrophy and heart failure. J Biol Chem 283:22295-22303. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98: 730-742, 2006. Burns-Hamuro LL, Ma Y, Kammerer S, Reineke U, Self C, Cook C, Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4072-7. Brunton LL, Hayes JS, Mayer SE (1979) Hormonally specific phosphorylation of cardiac troponin I and activation of glycogen phosphorylase. Nature 280:78-80. Buck M, Chojkier M. C / EBPbeta-Thr217 phosphorylation signaling contributes to the development of lung injury and fibrosis in mice. PLoS One. 2011;6(10):e25497. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD (2002) Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A 99:4586-4591. Bueno OF, Lips DJ, Kaiser RA Wilkins BJ, Dai YS, Glascock BJ, Klevitsky R, Hewett TE, Kimball TR, Aronow BJ, Doevendans PA, Molkentin JD (2004) Calcineurin Abeta gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ Res 94:91-99. Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128:388-400. Cappola TP. Molecular remodeling in human heart failure. J Am Coll Cardiol 51: 137-138, 2008. Cariolato L, Cavin S, Diviani D. A-kinase anchoring protein (AKAP)- Lbc anchors a PKN-based signaling complex involved in alpha1-adrenergic receptor-induced p38 activation. J Biol Chem 286: 7925-7937, 2011. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD (2004) PKA- phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signalling complex. Biochem J 381:587-592. Carlucci A, Lignitto L, Feliciello A. Control of mitochondria dynamics and oxidative metabolism by cAMP, AKAPs and the proteasome. Trends Cell Biol 18: 604-613, 2008. Carnegie GK, Smith FD, McConnachie G, Langeberg LK, Scott JD. AKAP-Lbc nucleates a protein kinase D activation scaffold. Mol Cell 15: 889 -899, 2004. Carnegie GK, Soughayer J, Smith FD, Pedroja BS, Zhang F, Diviani D, Bristow MR, Kunkel MT, Newton AC, Langeberg LK, Scott JD. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 32: 169 -179, 2008. Chaturvedi D, Poppleton HM, Stringfield T, Barbier A, Patel TB. Subcellular localization and biological actions of activated RSK1 are determined by its interactions with subunits of cyclic AMP-dependent protein kinase. Mol Cell Biol. 2006;26:4586-4600. Chen L, Kurokawa J, Kass RS. Phosphorylation of the A-kinase anchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel. J Biol Chem 280: 31347-31352, 2005. Chen L, Kurokawa J, Kass RS. Phosphorylation of the A-kinase- anchoring protein Yotiao contributes to protein kinase A regulation of a heart potassium channel. J Biol Chem 280: 31347-31352, 2005. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RS. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 104: 20990-20995, 2007. Chen PP, Patel JR, Rybakova IN, Walker JW, Moss RL. Protein kinase A-induced myofilament desensitization to Ca2+ as a result of phosphorylation of cardiac myosin-binding protein C. J Gen Physiol 136: 615-627, 2010. Christian F, Szaszak M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Gotz F, Zuhlke K, Moutty M, Gottert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Verli J, Gaspar R, Noack C, Bergmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E. Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes. J Biol Chem 286: 9079-9096, 2011. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S, Sugden PH (2007) Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 212:311-322. Consensus (1987). “Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).” N Engl J Med 316(23): 1429-1435. Cuello F, Snabaitis AK, Cohen MS, Taunton J, Avkiran M. Evidence for direct regulation of myocardial Na+ / H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK): effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation. Mol Pharmacol. 2007;71:799-806. De Arcangelis V, Soto D, Xiang Y (2008) Phosphodiesterase 4 and phosphatase 2A differentially regulate cAMP / protein kinase a signaling for cardiac myocyte contraction under stimulation ofbetal adrenergicreceptor. Mol Pharmacol 74:1453-1462. Diviani D, Abuin L, Cotecchia S, Pansier L. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J 23: 2811-2820, 2004. Diviani D, Dodge-Kafka KL, Li J, Kapiloff MS. A-kinase anchoring proteins: scaffolding proteins in the heart,” Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1742-53. Dobrev D, Wehrens XH (2014) Role of RyR2 phosphorylation in heart failure and arrhythmias: Controversies around ryanodine receptor phosphorylation in cardiac disease. Circ Res 114:1311-1319; discussion 1319. Dodge-Kafka, K. L., M. Gildart, J. Li, H. Thakur, and M. S. Kapiloff. 2018. Bidirectional regulation of HDAC5 by mAKAPbeta signalosomes in cardiac myocytes’, Journal of Molecular and Cellular Cardiology, 118: 13-25. Dodge-Kafka, K. L., A. Bauman, N. Mayer, E. Henson, L. Heredia, J. Ahn, T. McAvoy, A. C. Nairn and M. S. Kapiloff (2010). “cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP-specific phosphodiesterase PDE4D3.” J Biol Chem 285(15): 11078-11086. Dodge-Kafka, K. L. and M. S. Kapiloff (2006). “The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways.” Eur J Cell Biol 85(7): 593-602. Dodge-Kafka, K. L., J. Soughayer, G. C. Pare, J. J. Carlisle Michel, L. K. Langeberg, M. S. Kapiloff and J. D. Scott (2005). “The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways.” Nature 437(7058): 574-578. Dodge, K. L., S. Khouangsathiene, M. S. Kapiloff, R. Mouton, E. V. Hill, M. D. Houslay, L. K. Langeberg and J. D. Scott (2001). “mAKAP assembles a protein kinase A / PDE4 phosphodiesterase cAMP signaling module.” EMBO J 20(8): 1921-1930. Diviani D, Soderling J, Scott JD. AKAP-Lbc anchors protein kinase A and nucleates Galpha 12-selective Rho-mediated stress fiber formation. J Biol Chem 276: 44247-44257, 2001. Dodge KL, Khouangsathiene S, Kapiloff MS, Mouton R, Hill EV, Houslay MD, Langeberg LK, Scott JD. mAKAP assembles a protein kinase A / PDE4 phosphodiesterase cAMP signaling module. EMBO J 20: 1921-1930, 2001. Dodge-Kafka KL, Bauman A, Kapiloff MS, A-kinase anchoring proteins as the basis for cAMP signaling,” Handb Exp Pharmacol. 2008;(186):3-14. Dodge-Kafka KL, Bauman A, Mayer N, Henson E, Heredia L, Ahn J, McAvoy T, Nairn AC, Kapiloff MS. cAMP-stimulated protein phosphatase 2A activity associated with muscle A kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation and activity of the cAMP- specific phosphodiesterase PDE4D3. J Biol Chem. 2010;285:11078-11086. Dodge-Kafka KL, Kapiloff MS, “The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways,” Eur J Cell Biol. 2006 Jul;85(7):593-602. Epub 2006 Feb 7. Review. Dodge-Kafka KL, Langeberg L, Scott JD (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of A-kinase anchoring proteins. Circ Res 98:993-1001. duBell WH, Lederer WJ, Rogers TB (1996) Dynamic modulation of excitation-contraction coupling by protein phosphatases in rat ventricular myocytes. J Physiol 493 ( Pt 3):793- 800. duBell WH, Gigena MS, Guatimosim S, Long X, Lederer WJ, Rogers TB (2002) Effects of PP1 / PP2A inhibitor calyculin A on the E-C coupling cascade in murine ventricular myocytes. Am J Physiol Heart Circ Physiol 282:H38-48. Dulhunty AF, Beard NA, Pouliquin P, Casarotto MG (2007) Agonists and antagonists of the cardiac ryanodine receptor: potential therapeutic agents? Pharmacol Ther 113:247-263. Dummler BA, Hauge C, Silber J, Yntema HG, Kruse LS, Kofoed B, Hemmings BA, Alessi DR, Frodin M. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem. 2005;280:13304-13314 Edgley AJ, Krum H, Kelly DJ. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther. 2012;30(1):e30-40. Eide T, Coghlan V, Orstavik S, Holsve C, Solberg R, Skalhegg BS, Lamb NJ, Langeberg L, Fernandez A, Scott JD, Jahnsen T, Tasken K. Molecular cloning, chromosomal localization, and cell cycle-dependent subcellular distribution of the A-kinase anchoring protein, AKAP95. Exp Cell Res 238: 305-316, 1998. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T, Functional anatomy of SiRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate, The EMBO Journal, Vol. 20, No. 23, pp. 6877-6888, 2001. Endo S, Zhou X, Connor J, Wang B, Shenolikar S (1996) Multiple structural elements define the specificity of recombinant human inhibitor-1 as a protein phosphatase-1 inhibitor. Biochemistry 35:5220-5228. Escobar M, Cardenas C, Colavita K, Petrenko NB, Franzini- Armstrong C. Structural evidence for perinuclear calcium microdo- mains in cardiac myocytes. J Mol Cell Cardiol 50: 451-459, 2011. Fabiato A. Calcium-induced release of calcium from the cardiac sarco- plasmic reticulum. Am J Physiol Cell Physiol 245: C1-C14, 1983. Farah CS, Reinach FC. The troponin complex and regulation of muscle contraction. FASEB J 9: 755-767, 1995. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ, Jr., Spudich S, De Girolami U, Seidman JG, Seidman C, Muntoni F, Muehle G, Johnson W, McDonough B (1999) Missense mutations in the rod domain of the lamin NC gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 341:1715-1724. Faul C, Dhume A, Schecter AD, Mundel P. Protein kinase A, Ca2+ / calmodulin-dependent kinase II, and calcineurin regulate the intracellular trafficking of myopodin between the Z-disc and the nucleus of cardiac myocytes. Mol Cell Biol 27: 8215-8227, 2007. Fink MA, Zakhary DR, Mackey JA, Desnoyer RW, Apperson- Hansen C, Damron DS, Bond M. AKAP-mediated targeting of protein kinase a regulates contractility in cardiac myocytes. Circ Res 88: 291- 297, 2001. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99:816-828. Fodstad H, Swan H, Laitinen P, Piippo K, Paavonen K, Viitasalo M, Toivonen L, Kontula K. Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med 36, Suppl 1: 53-63, 2004. Francis SH, Corbin JD. Structure and function of cyclic nuleotide- dependent protein kinases. Annu Rev Physiol 56: 237-272, 1994. Fraser ID, Tavalin SJ, Lester LB, Langeberg LK, Westphal AM, Dean RA, Marrion NV, Scott JD. A novel lipid-anchored A-kinase anchoring protein facilitates cAMP-responsive membrane events. EMBO J 17: 2261-2272, 1998. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580 -1589, 2004. Friday BB, Mitchell PO, Kegley KM, Pavlath GK (2003) Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation 71:217-227. Fuller MD, Emrick MA, Sadilek M, Scheuer T, Catterall WA. Molecular mechanism of calcium channel regulation in the fight-or-flight response. Sci Signal 3: ra70, 2010. Gaffin RD, Pena JR, Alves MS, Dias FA, Chowdhury SA, Heinrich LS, Goldspink PH, Kranias EG, Wieczorek DF, Wolska BM. Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J. Mol. Cell. Cardiol. 2011. Gao T, Yatani A, Dell’Acqua ML, Sako H, Green SA, Dascal N, Scott JD, Hosey MM. cAMP-dependent regulation of cardiac L-type Ca2+ channels requires membrane targeting of PKA and phosphorylation of channel subunits. Neuron 19: 185-196, 1997. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 101: 7618-7623, 2004. Gelb BD, Tartaglia M. RAS signaling pathway mutations and hypertro- phic cardiomyopathy: getting into and out of the thick of it. J Clin Invest. 2011;121:844-847. GentilucciL,TolomelliA,SquassabiaF.Peptidesandpeptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 13: 2449- 2466, 2006. Gerber, Y., S. A. Weston, M. Enriquez-Sarano, C. Berardi, A. M. Chamberlain, S. M. Manemann, R. Jiang, S. M. Dunlay and V. L. Roger (2016). “Mortality Associated With Heart Failure After Myocardial Infarction: A Contemporary Community Perspective.” Circ Heart Fail 9(1): e002460. Gigena MS, Ito A, Nojima H, Rogers TB (2005) A B56 regulatory subunit of protein phosphatase 2A localizes to nuclear speckles in cardiomyocytes. Am J Physiol Heart Circ Physiol 289:H285-294. Go AS et al. (2014) Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 129:e28-e292. Gold MG, Lygren B, Dokurno P, Hoshi N, McConnachie G, Tasken K, Carlson CR, Scott JD, Barford D. Molecular basis of AKAP specificity for PKA regulatory subunits. Mol Cell 24: 383-395, 2006. Goldschmidt-Clermont PJ, Seo DM, Wang L, Beecham GW, Liu ZJ, Vazquez-Padron RI, Dong C, Hare JM, Kapiloff MS, Bishopric NH, Pericak-Vance M, Vance JM, Velazquez OC, “Inflammation, stem cells and atherosclerosis genetics,” Curr Opin Mol Ther. 2010 Dec;12(6):712-23. Review. Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. Science. 2011;332:680-686. Gould KL, Bretscher A, Esch FS, Hunter T. cDNA cloning and sequencing of the protein-tyrosine kinase substrate, ezrin, reveals homol- ogy to band 4.1. EMBO J 8: 4133-4142, 1989. Gray PC, Scott JD, Catterall WA. Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins. Curr Opin Neurobiol 8: 330-334, 1998. Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56:56-64. Group, Consensus Trial Study. 1987. ‘Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)’, New England Journal of Medicine, 316: 1429-35. Guo T, Cornea RL, Huke S, Camors E, Yang Y, Picht E, Fruen BR, Bers DM. Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res 106: 1743-1752, 2010. Guo, H., B. Liu, L. Hou, E. The, G. Li, D. Wang, Q. Jie, W. Che and Y. Wei (2015). “The role of mAKAPbeta in the process of cardiomyocyte hypertrophy induced by angiotensin II.” Int J Mol Med 35(5): 1159-1168. Hagemann D, Xiao RP. Dual site phospholamban phosphorylation and its physiological relevance in the heart. Trends Cardiovasc Med 12: 51-56, 2002. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241:42-52. Hanlon M, Sturgill TW, Sealy L (2001) ERK2- and p90(Rsk2)-dependent pathways regulate the CCAAT / enhancer-binding protein-beta interaction with serum response factor. J Biol Chem 276:38449-38456. Harada H, Becknell B, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3: 413-422, 1999. Hayes JS, Brunton LL, Mayer SE (1980) Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin El. J Biol Chem 255:5113-5119. Heidenreich, P. A., N. M. Albert, L. A. Allen, D. A. Bluemke, J. Butler, G. C. Fonarow, J. S. Ikonomidis, O. Khavjou, M. A. Konstam, T. M. Maddox, G. Nichol, M. Pham, I. L. Pina, J. G. Trogdon, C. American Heart Association Advocacy Coordinating, T. Council on Arteriosclerosis, B. Vascular, R. Council on Cardiovascular, Intervention, C. Council on Clinical, E. Council on, Prevention and C. Stroke (2013). “Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association.” Circ Heart Fail 6(3): 606-619. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 7:589-600. Hell JW. Beta-adrenergic regulation of the L-type Ca2+ channel CaV1.2 by PKA rekindles excitement. Sci Signal 3: pe33, 2010. Henn V, Edemir B, Stefan E, Wiesner B, Lorenz D, Theilig F, Schmitt R, Vossebein L, Tamma G, Beyermann M, Krause E, Herberg FW, Valenti G, Bachmann S, Rosenthal W, Klussmann E. Identification of a novel A-kinase anchoring protein 18 isoform and evidence for its role in the vasopressin-induced aquaporin-2 shuttle in renal principal cells. J Biol Chem 279: 26654-26665, 2004. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 358: 1370-1380, 2008. Ho SN, Thomas DJ, Timmerman LA, Li X, Francke U, Crabtree GR (1995) NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem 270:19898-19907. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J 18:893-903. Houser SR (2014) Role ofRyR2 phosphorylation in heart failure and arrhythmias: protein kinase A-mediated hyperphosphorylation of the ryanodine receptor at serine 2808 does not alter cardiac contractility or cause heart failure and arrhythmias. Circ Res 114:1320-1327; discussion 1327. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. D-AKAP2, a novel protein kinase A anchoring protein with a putative RGS domain. Proc Natl Acad Sci USA 94: 11184-11189, 1997. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. Identification of a novel dual specificity protein kinase A anchoring protein, D-AKAP1. J Biol Chem 272: 8057-8064, 1997. Huang LJ, Durick K, Weiner JA, Chun J, Taylor SS. Identification of a novel protein kinase A anchoring protein that binds both type I and type II regulatory subunits. J Biol Chem. 1997;272:8057-8064. Hulme JT, Ahn M, Hauschka SD, Scheuer T, Catterall WA. A novel leucine zipper targets AKAP15 and cyclic AMP-dependent protein ki- nase to the C terminus of the skeletal muscle Ca2 channel and modu- lates its function. J Biol Chem 277: 4079-4087, 2002. Hulme JT, Lin TW, Westenbroek RE, Scheuer T, Catterall WA. Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchor- ing protein 15. Proc Natl Acad Sci USA 100: 13093-13098, 2003. Hulme JT, Westenbroek RE, Scheuer T, Catterall WA. Phosphory- lation of serine 1928 in the distal C-terminal domain of cardiac CaV1.2 channels during beta1-adrenergic regulation. Proc Natl Acad Sci USA 103: 16574 -16579, 2006. Hundsrucker C, Klussmann E. Direct AKAP-mediated protein-protein interactions as potential drug targets. Hand Exp Pharmacol 186: 483- 503, 2008. Hundsrucker C, Krause G, Beyermann M, Prinz A, Zimmermann B, Diekmann O, Lorenz D, Stefan E, Nedvetsky P, Dathe M, Christian F, McSorley T, Krause E, McConnachie G, Herberg FW, Scott JD, Rosenthal W, Klussmann E. High-affinity AKAP7delta-protein kinase A interaction yields novel protein kinase A-anchoring disruptor peptides. Biochem J 396: 297-306, 2006. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel- Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468 -472, 2001. Janknecht R, Hipskind RA, Houthaeve T, Nordheim A, Stunnenberg HG (1992) Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties. EMBO J 11:1045-1054. Jugdutt BI (2003) Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3:1-30. Kamisago M, Sharma SD, DePalma SR, Solomon S, Sharma P, McDonough B, Smoot L, Mullen MP, Woolf PK, Wigle ED, Seidman JG, Seidman CE. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343: 1688-1696, 2000. Kammerer S, Burns-Hamuro LL, Ma Y, Hamon SC, Canaves JM, Shi MM, Nelson MR, Sing CF, Cantor CR, Taylor SS, Braun A. Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci USA 100: 4066-4071, 2003. Kapiloff MS, Chandrasekhar KD, “A-kinase anchoring proteins: temporal and spatial regulation of intracellular signal transduction in the cardiovascular system,” Journal Cardiovasc Pharmacol. 2011 Oct;58(4):337-8. Kapiloff MS, Jackson N, Airhart N. mAKAP and the ryanodine receptor are part of a multi-component signaling complex on the cardiomyocyte nuclear envelope. J Cell Sci 114: 3167-3176, 2001. Kapiloff MS, Piggott LA, Sadana R, Li J, Heredia LA, Henson E, Efendiev R, Dessauer CW, “An adenylyl cyclase-mAKAPbeta signaling complex regulates cAMP levels in cardiac myocytes,” J Biol Chem. 2009 Aug 28;284(35):23540-6. Kapiloff MS, Mathis JM, Nelson CA, Lin CR, Rosenfeld MG (1991) Calcium / calmodulin- dependent protein kinase mediates a pathway for transcriptional regulation. Proc Natl Acad Sci US A 88:3710-3714. Kapiloff MS, Schillace RV, Westphal AM, Scott JD. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J Cell Sci 112: 2725-2736, 1999. Kato Y, Zhao M, Morikawa A, Sugiyama T, Chakravortty D, Koide N, Yoshida T, Tapping RI, Yang Y, Yokochi T, Lee JD (2000) Big mitogen-activated kinase regulates multiple members of the MEF2 protein family. J Biol Chem 275:18534-18540. Keely SL (1977) Activation of cAMP-dependent protein kinase without a corresponding increase in phosphorylase activity. Res Commun Chem Pathol Pharmacol 18:283-290. Keely SL (1979) Prostaglandin El activation of heart cAMP-dependent protein kinase: apparent dissociation of protein kinase activation from increases in phosphorylase activity and contractile force. Mol Pharmacol 15:235-245. Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, Maillet M, York AJ, Lorenz JN, Zimmermann WH, Meloche S, Molkentin JD. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res. 2011;108:176-183. Kehat I, Molkentin JD. Molecular pathways underlying cardiac re- modeling during pathophysiological stimulation. Circulation. 2010;122:2727-2735. Kentish JC, McCloskey DT, Layland J, Palmer S, Leiden JM, Martin AF, Solaro RJ. Phosphorylation of troponin I by protein kinase A accelerates relaxation and crossbridge cycle kinetics in mouse ventric- ular muscle. Circ Res 88: 1059-1065, 2001. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial in- farction in the mouse. J Am Coll Cardiol 46: 2116-2124, 2005. Kim Y, Phan D, van Rooij E, Wang DZ, McAnally J, Qi X, Richardson JA, Hill JA, Bassel- Duby R, Olson EN (2008) The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 118:124-132. Kimura TE, Jin J, Zi M, Prehar S, Liu W, Oceandy D, Abe J, Neyses L, Weston AH, Cartwright EJ, Wang X. Targeted deletion of the extracel- lular signal-regulated protein kinase 5 attenuates hypertrophic response and promotes pressure overload-induced apoptosis in the heart. Circ Res. 2010;106:961-970. Kinderman FS, Kim C, von Daake S, Ma Y, Pham BQ, Spraggon G, Xuong NH, Jennings PA, Taylor SS. A dynamic mechanism for AKAP binding to RII isoforms of cAMP-dependent protein kinase. Mol Cell 24: 397-408, 2006. Klussmann E, Edemir B, Pepperle B, Tamma G, Henn V, Klauschenz E, Hundsrucker C, Maric K, Rosenthal W. Ht31: the first protein kinase A anchoring protein to integrate protein kinase A and Rho signaling. FEBS Lett 507: 264-268, 2001. Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T, Makino S, Manabe T, Murata M, Ogawa S. Significance of ERK cascade compared with JAK / STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2000;279(4):H1635-1644. Kontaridis MI, Yang W, Bence KK, Cullen D, Wang B, Bodyak N, Ke Q, Hinek A, Kang PM, Liao R, Neel BG. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase / mitogen-activated protein kinase and RhoA signaling pathways. Circulation. 2008;117:1423-1435. Kritzer MD, Li J, Dodge-Kafka K, Kapiloff MS, “AKAPs: the architectural underpinnings of local cAMP signaling,” J Mol Cell Cardiol. 2012 Feb;52(2):351-8. Kritzer, M. D., J. Li, C. L. Passariello, M. Gayanilo, H. Thakur, J. Dayan, K. Dodge-Kafka and M. S. Kapiloff (2014). “The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure.” Circ Heart Fail 7(4): 663-672. Kumar, D., T. A. Hacker, J. Buck, L. F. Whitesell, E. H. Kaji, P. S. Douglas and T. J. Kamp (2005). “Distinct mouse coronary anatomy and myocardial infarction consequent to ligation.” Coron Artery Dis 16(1): 41-44. Lacana E, Maceyka M, Milstien S, Spiegel S. Cloning and character- ization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J Biol Chem 277: 32947-32953, 2002. Layland J, Solaro RJ, Shah AM. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66: 12-21, 2005. Lechward K, Awotunde OS, Swiatek W, Muszynska G (2001) Protein phosphatase 2A: variety of forms and diversity of functions. Acta Biochim Pol 48:921-933. Lehnart, S. E., X. H. Wehrens, S. Reiken, S. Warrier, A. E. Belevych, R. D. Harvey, W. Richter, S. L. Jin, M. Conti and A. R. Marks (2005). “Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias.” Cell 123(1): 25-35. Lester LB, Langeberg LK, Scott JD. Anchoring of protein kinase A facilitates hormone-mediated insulin secretion. Proc Natl Acad Sci USA 94: 14942-14947, 1997. Li CL, Sathyamurthy A, Oldenborg A, Tank D, Ramanan N (2014) SRF phosphorylation by glycogen synthase kinase-3 promotes axon growth in hippocampal neurons. J Neurosci 34:4027-4042. Li H, Adamik R, Pacheco-Rodriguez G, Moss J, Vaughan M. Protein kinase A-anchoring (AKAP) domains in brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2). Proc Natl Acad Sci USA 100: 1627-1632, 2003. Li J, Kritzer MD, Michel JJ, Le A, Thakur H, Gayanilo M, Passariello CL, Negro A, Danial JB, Oskouei B, Sanders M, Hare JM, Hanauer A, Dodge-Kafka K, Kapiloff MS, “Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy,” Circ Res. 2013 Jan 4;112(1):128-39. Li J, Negro A, Lopez J, Bauman AL, Henson E, Dodge-Kafka K, Kapiloff MS. The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. J Mol Cell Cardiol 48: 387-394, 2010. Li J, Negro A, Lopez J, Bauman AL, Henson E, Dodge-Kafka K, Kapiloff MS, “The mAKAPbeta scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin,” J Mol Cell Cardiol. 2010 Feb;48(2):387-94. Li J, Vargas MA, Kapiloff MS, Dodge-Kafka KL, Regulation of MEF2 transcriptional activity by calcineurin / mAKAP complexes,” Exp Cell Res. 2013 Feb 15;319(4):447-54. Li, J., S. Aponte Paris, H. Thakur, M. S. Kapiloff, and K. L. Dodge-Kafka. 2019. ‘Muscle A-kinase-anchoring protein-beta-bound calcineurin toggles active and repressive transcriptional complexes of myocyte enhancer factor 2D’, Journal of Biological Chemistry, 294: 2543-54. Li M, Makkinje A, Damuni Z (1996) Molecular identification of I1PP2A, a novel potent heat- stable inhibitor protein of protein phosphatase 2A. Biochemistry 35:6998-7002. Liu Q, Hofmann PA (2004) Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apopfosis of cardiac myocytes. Am J Physiol Heart Circ Physiol 286:H2204- 2212. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta- adrenergic signaling in heart failure? Circ Res 93: 896-906, 2003. Lu JT, Kass RS. Recent progress in congenital long QT syndrome. Curr Opin Cardiol 25: 216-221, 2010. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Lorenz D, Wiesner B, Rosenthal W, Zaccolo M, Tasken K, Klussmann E. AKAP-complex regulates the Ca2+ reuptake into heart sarcoplasmic reticulum. EMBO Rep 8: 1061-1067, 2007. Lygren B, Tasken K. The potential use of AKAP18delta as a drug target in heart failure patients. Expert Opin Biol Ther 8: 1099-1108, 2008. Mack CP (2011) Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vase Biol 31:1495-1505. Mackenzie KF, Topping EC, Bugaj-Gaweda B, Deng C, Cheung YF, Olsen AE, Stockard CR, High Mitchell L, Baillie GS, Grizzle WE, De Vivo M, Houslay MD, Wang D, Bolger GB (2008) Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change. Biochem J 411:361- 369. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD (2000) ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J Biol Chem 275:16609-16617. Maloney DJ, Hecht SM. Synthesis of a potent and selective inhibitor of p90 Rsk. Org Lett. 2005;7:1097-1099. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-255. Maruyama Y, Nishida M, Sugimoto Y, Tanabe S, Turner JH, Kozasa T, Wada T, Nagao T, Kurose H. Galpha(12 / 13) mediates alpha(1)- adrenergic receptor-induced cardiac hypertrophy. Circ Res 91: 961-969, 2002. Martinez, E. C., C. L. Passariello, J. Li, C. J. Matheson, K. Dodge-Kafka, P. Reigan and M. S. Kapiloff (2015). “RSK3: A regulator of pathological cardiac remodeling.” IUBMB Life 67(5): 331-337.Marx SO, Kurokawa J, Reiken S, Motoike H, D’Armiento J, Marks AR, Kass RS. Requirement of a macromolecular signaling complex for beta adrenergic receptor modulation of the KCNQ1-KCNE1 potassium channel. Science 295: 496 -499, 2002. Marx SO, Reiken S, Hisamatsu Y, Gaburjakova M, Gaburjakova J, Yang YM, Rosemblit N, Marks AR. Phosphorylation-dependent regulation of ryanodine receptors: a novel role for leucine / isoleucine zippers. J Cell Biol. 2001;153:699-708. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks AR. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regula tion in failing hearts. Cell 101: 365-376, 2000. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999. Mayers CM, Wadell J, McLean K, Venere M, Malik M, Shibata T, Driggers PH, Kino T, Guo XC, Koide H, Gorivodsky M, Grinberg A, Mukhopadhyay M, Abu-Asab M, Westphal H, Segars JH. The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. J Biol Chem 285: 12344-12354, 2010. Mccartney S, Little BM, Langeberg LK, Scott JD (1995) Cloning and Characterization of a- Kinase Anchor Protein-100 (AkaplOO) - a Protein That Targets a-Kinase to the Sarcoplasmic-Reticulum. J Biol Chem 270:9327-9333. McConnell BK, Popovic Z, Mal N, Lee K, Bautista J, Forudi F, Schwartzman R, Jin JP, Penn M, Bond M. Disruption of protein kinase A interaction with A-kinase-anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J Biol Chem 284: 1583-1592, 2009. McCright B, Rivers AM, Audlin S, Virshup DM (1996) The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 271:22081-22089. McKinsey TA, Kass DA. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov. 2007;6:617-635. Miano JM (2010) Role of serum response factor in the pathogenesis of disease. Lab Invest 90:1274-1284. Michel JJ, Townley IK, Dodge-Kafka KL, Zhang F, Kapiloff MS, Scott JD, “Spatial restriction of PDK1 activation cascades by anchoring to mAKAPalpha,” Mol Cell. 2005 Dec 9;20(5):661-72. Michele DE, Gomez CA, Hong KE, Westfall MV, Metzger JM. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. Circ. Res. 2002;91(3):255-262. Monovich L, Vega RB, Meredith E, Miranda K, Rao C, Capparelli M, Lemon DD, Phan D, Koch KA, Chapo JA, Hood DB, McKinsey TA (2010) A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class Ila histone deacetylase kinase. FEBS Lett 584:631-637. Morissette MR, Sah VP, Glembotski CC, Brown JH. The Rho effector, PKN, regulates ANF gene transcription in cardiomyocytes through a serum response element. Am J Physiol Heart Circ Physiol 278: H1769-H1774, 2000. Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, de Visser M, Schwartz K (2000) Identification of mutations in the gene encoding lamins A / C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMDlB). Hum Mol Genet 9:1453-1459. Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 276: 18953-18959, 2001. Naga Prasad SV, Laporte SA, Chamberlain D, Caron MG, Barak L, Rockman HA. Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor / beta-arrestin complex. J Cell Biol 158: 563-575, 2002. Nakagami H, Kikuchi Y, Katsuya T, Morishita R, Akasaka H, Saitoh S, Rakugi H, Kaneda Y, Shimamoto K, Ogihara T. Gene polymor- phism of myospryn (cardiomyopathy-associated 5) is associated with left ventricular wall thickness in patients with hypertension. Hypertens Res 30: 1239-1246, 2007. Nakamura A, Rokosh DG, Paccanaro M, Yee RR, Simpson PC, Grossman W, Foster E. LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. Am J Physiol Heart Circ Physiol. 2001;281:H1104-1112 Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD, Ronai Z. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 117: 941-952, 2004. Nauert JB, Klauck TM, Langeberg LK, Scott JD. Gravin, an autoan- tigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol 7: 52-62., 1997. Naya FJ, Olson E (1999) MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr Opin Cell Biol 11:683-688. Naya FJ, Wu C, Richardson JA, Overbeek P, Olson EN (1999) Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 126:2045-2052. Nerbonne JM, Kass RS. Molecular physiology of cardiac repolariza-tion. Physiol Rev 85: 1205-1253, 2005. Negro A, Dodge-Kafka K, Kapiloff MS, “Signalosomes as Therapeutic Targets,” Prog Pediatr Cardiol. 2008 Apr; 25(1):51-56. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, Santana LF, McKnight GS. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. Circ Res 107: 747-756, 2010. Newlon MG, Roy M, Morikis D, Hausken ZE, Coghlan V, Scott JD, Jennings PA (1999) The molecular basis for protein kinase A anchoring revealed by solution NMR. Nat Struct Biol 6:222-227. Nicol RL, Frey N, Pearson G, Cobb M, Richardson J, Olson EN. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001;20:2757-2767. Niggli E, Lederer WJ. Voltage-independent calcium release in heart muscle. Science 250: 565-568, 1990. Papa S, Sardanelli AM, Scacco S, Petruzzella V, Technikova- Dobrova Z, Vergari R, Signorile A. The NADH: ubiquinone oxidoreductase (complex I) of the mammalian respiratory chain and the cAMP cascade. J Bioenerg Biomembr 34: 1-10, 2002. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta- domain of the von Hippel-Lindau protein. Nat Cell Biol 2:423-427. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW, Dorn GW, 2nd, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 2007;101(3):313-321. Okumura, S., G. Takagi, J. Kawabe, G. Yang, M. C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner and Y. Ishikawa (2003). “Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload.” Proc Natl Acad Sci U S A 100(17): 9986-9990. Olson GL, Cantor CR, Braun A, Taylor SS. Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci USA 100: 4072-4077, 2003. Pare GC, Bauman AL, McHenry M, Michel JJ, Dodge-Kafka KL, Kapiloff MS. The mAKAP complex participates in the induction of cardiac myocyte hypertrophy by adrenergic receptor signaling. J Cell Sci 118: 5637-5646, 2005. Pare GC, Easlick JL, Mislow JM, McNally EM, Kapiloff MS. Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res 303: 388-399, 2005. Passariello, C. L., J. Li, K. Dodge-Kafka and M. S. Kapiloff (2015). “mAKAP-a master scaffold for cardiac remodeling.” J Cardiovasc Pharmacol 65(3): 218-225. Passariello CL, Martinez EC, Thakur H, Cesareo M, Li J, Kapiloff MS (2016) RSK3 is required for concentric myocyte hypertrophy in an activated Rafl model for Noonan syndrome. J Mol Cell Cardiol 93:98-105. Passariello CL, Gayanilo M, Kritzer MD, Thakur H, Cozacov Z, Rusconi F, Wieczorek D, Sanders M, Li J, Kapiloff MS (2013) p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in alpha-tropomyosin Glul 80Gly transgenic mice. Am J Physiol Heart Circ Physiol 305:H1010-1019. Patel HH, Hamuro LL, Chun BJ, Kawaraguchi Y, Quick A, Re- bolledo B, Pennypacker J, Thurston J, Rodriguez-Pinto N, Self C, Olson G, Insel PA, Giles WR, Taylor SS, Roth DM. Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function. J Biol Chem 285: 27632-27640, 2010. Pawson CT, Scott JD. Signal integration through blending, bolstering and bifurcating of intracellular information. Nat Struct Mol Biol 17: 653-658, 2010. Pawson T, Nash P (2003) Assembly of cell regulatory systems through protein interaction domains. Science 300:445-452. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, Damilano F, Dunlop AJ, Pawson C, Walser R, Levi R, Altruda F, Silengo L, Langeberg LK, Neubauer G, SH, Lembo G, Wymann MP, Wetzker R, Houslay MD, Iaccarino G, Scott JD, Hirsch E. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell 42: 84 -95, 2011. Perrino C, Feliciello A, Schiattarella GG, Esposito G, Guerriero R, Zaccaro L, Del Gatto A, Saviano M, Garbi C, Carangi R, Di Lorenzo E, Donato G, Indolfi C, Avvedimento VE, Chiariello M. AKAP121 downregulation impairs protective cAMP signals, promotes mitochon- drial dysfunction, and increases oxidative stress. Cardiovasc Res 88: 101–110, 2010. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560. Peter AK, Bjerke MA, Leinwand LA (2016) Biology of the cardiac myocyte in heart disease. Mol Biol Cell 27:2149-2160. Ponikowski, P., A. A. Voors, S. D. Anker, H. Bueno, J. G. Cleland, A. J. Coats, V. Falk, J. R. Gonzalez-Juanatey, V. P. Harjola, E. A. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis, B. Pieske, J. P. Riley, G. M. Rosano, L. M. Ruilope, F. Ruschitzka, F. H. Rutten, P. van der Meer and M. Authors / Task Force (2016). “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.” Eur Heart J 37(27): 2129-2200. Potthoff MJ, Olson EN (2007) MEF2: a central regulator of diverse developmental programs. Development 134:4131-4140. Prabhakar R, Boivin GP, Grupp IL, Hoit B, Arteaga G, Solaro JR, Wieczorek DF. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J. Mol. Cell. Cardiol. 2001;33(10):1815-1828. Prasad, K. M., Y. Xu, Z. Yang, S. T. Acton and B. A. French (2011). “Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution.” Gene Ther 18(1): 43-52. Rababah A, Craft JW, Jr., Wijaya CS, Atrooz F, Fan Q, Singh S, Guillory AN, Katsonis P, Lichtarge 0, McConnell BK (2013) Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP). J Mol Biol 425:3277-3288, Ranganathan A, Pearson GW, Chrestensen CA, Sturgill TW, Cobb MH (2006) The MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch Biochem Biophys 449:8-16. Reiken S, Gaburjakova M, Gaburjakova J, He Kl KL, Prieto A, Becker E, Yi Gh GH, Wang J, Burkhoff D, Marks AR (2001) beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848. Resjo S, Oknianska A, Zolnierowicz S, Manganiello V, Degerman E (1999) Phosphorylation and activation of phosphodiesterase type 38 (PDE3B) in adipocytes in response to serine / threonine phosphatase inhibitors: deactivation of PDE3B in vitro by protein phosphatase type 2A. Biochem J 341 (Pt 3):839-845. Reynolds JG, McCalmon SA, Tomczyk T, Naya FJ. Identification and mapping of protein kinase A binding sites in the costameric protein myospryn. Biochim Biophys Acta 1773: 891-902, 2007. Richards SA, Dreisbach VC, Murphy LO, Blenis J. Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1. Mol Cell Biol. 2001;21:7470-7480. Rivera VM, Miranti CK, Misr;i RP, Ginty DD, Chen RH, Blenis J, Greenberg ME (1993) A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol 13:6260-6273. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-span- ning receptors and heart function. Nature 415: 206-212, 2002. Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of atrial-specific and in- ducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA. 1991;88:8277-8281. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-e209, 2011. Rose BA, Force T, Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010;90:1507-1546. Russell MA, Lund LM, Haber R, McKeegan K, Cianciola N, Bond M. The intermediate filament protein, synemin, is an AKAP in the heart. Arch Biochem Biophys 456: 204 -215, 2006. Sadoshima J, Qiu Z, Morgan JP, Izumo S. Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling. Circ. Res. 1995;76(1):1-15. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007;401:29-38. Schiattarella GG, Hill JA (2015) Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131:1435-1447. Scholten A, Poh MK, van Veen TA, van Breukelen B, Vos MA, Heck AJ. Analysis of the cGMP / cAMP interactome using a chemical proteom- ics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. J Proteome Res 5: 1435-1447, 2006. Scholten A, van Veen TA, Vos MA, Heck AJ. Diversity of cAMP- dependent protein kinase isoforms and their anchoring proteins in mouse ventricular tissue. J Proteome Res 6: 1705-1717, 2007. Schulze DH, Muqhal M, Lederer WJ, Ruknudin AM. Sodium / calcium exchanger (NCX1) macromolecular complex. J Biol Chem 278: 28849 -28855, 2003. Scott JD, Dessauer CW, Tasken K (2013) Creating order from chaos: cellular regulation by kinase anchoring. Annu Rev Pharmacol Toxicol 53:187-210. Scott, J. D. and T. Pawson (2009). “Cell signaling in space and time: where proteins come together and when they’re apart.” Science 326(5957): 1220-1224. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007: cm8, 2007. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24: 97-106, 2009. Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chern 271:16526-16534. Sfichi-Duke L, Garcia-Cazarin ML, Sumandea CA, Sievert GA, Balke CW, Zhan DY, Morimoto S, Sumandea MP. Cardiomyopathy- causing deletion K210 in cardiac troponin T alters phosphorylation propensity of sarcomeric proteins. J Mol Cell Cardiol 48: 934-942, 2010. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. J Clin Invest 120: 4375-4387, 2010. Shan J, Kushnir A, Betzenhauser MJ, Reiken S, Li J, Lehnart SE, Lindegger N, Mongillo M, Mohler PJ, Marks AR. Phosphorylation of the ryanodine receptor mediates the cardiac fight or flight response in mice. J Clin Invest 120: 4388-4398, 2010. Sharma K, Kass DA (2014) Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115:79-96. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P, Chang H. Intramyocardial injection of naked DNA encoding HIF- 1alpha / VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54: 576-583, 2002. Silva, J. M., M. Z. Li, K. Chang, W. Ge, M. C. Golding, R. J. Rickles, D. Siolas, G. Hu, P. J. Paddison, M. R. Schlabach, N. Sheth, J. Bradshaw, J. Burchard, A. Kulkarni, G. Cavet, R. Sachidanandam, W. R. McCombie, M. A. Cleary, S. J. Elledge and G. J. Hannon (2005). “Second-generation shRNA libraries covering the mouse and human genomes.” Nat Genet 37(11): 1281-1288. Singh A, Redden JM, Kapiloff MS, Dodge-Kafka KL, “The large isoforms of A-kinase anchoring protein 18 mediate the phosphorylation of inhibitor-1 by protein kinase A and the inhibition of protein phosphatase 1 activity,” Mol Pharmacol. 2011 Mar;79(3):533-40. Skroblin P, Grossmann S, Schafer G, Rosenthal W, Klussmann E. Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol 283: 235-330, 2010. Smith FD, Langeberg LK, Cellurale C, Pawson T, Morrison DK, Davis RJ, Scott JD. AKAP-Lbc enhances cyclic AMP control of the ERK1 / 2 cascade. Nat Cell Biol 12: 1242-1249, 2010. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 ki- nase (RSK) reveals an unexpected role for RSK in cancer cell prolifera- tion. Cancer Res. 2005;65:1027-1034. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix proteolysis and heart failure. Circ. Res. 2013;112(1):195-208. Steinberg SF, Brunton LL (2001) Cornpartrnentation of G protein-coupled signaling pathways in cardiac rnyocytes. Annu Rev Pharmacol Toxicol 41:751-773. Stelzer JE, Patel JR, Walker JW, Moss RL. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofi- brillar force responses to protein kinase A phosphorylation. Circ Res 101: 503-511, 2007. Sumandea CA, Garcia-Cazarin ML, Bozio CH, Sievert GA, Balke CW, Sumandea MP. Cardiac troponin T, a sarcomeric AKAP, tethers protein kinase A at the myofilaments. J Biol Chem 286: 530-541, 2011 Takeishi Y, Huang Q, Abe J, Che W, Lee JD, Kawakatsu H, Hoit BD, Berk BC, Walsh RA. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomy- opathy. Cardiovasc Res. 2002;53:131-137. Terrenoire C, Houslay MD, Baillie GS, Kass RS. The cardiac IKs potassium channel macromolecular complex includes the phosphodies terase PDE4D3. J Biol Chem 284: 9140-9146, 2009. Thomas GM, Rumbaugh GR, Harrar DB, Huganir RL. Ribosomal S6 kinase 2 interacts with and phosphorylates PDZ domain-containing proteins and regulates AMPA receptor transmission. Proc Natl Acad Sci USA. 2005;102:15006-15011. Tingley WG, Pawlikowska L, Zaroff JG, Kim T, Nguyen T, Young SG, Vranizan K, Kwok PY, Whooley MA, Conklin BR. Gene-trapped mouse embryonic stem cell-derived cardiac myocytes and human genet- ics implicate AKAP10 in heart rhythm regulation. Proc Natl Acad Sci USA 104: 8461-8466, 2007. Treisrnan R (1985) Transient accumulation of c-fos RNA following serum stimulation requires a conserved 5’ element and c-fos 3’ sequences. Cell 42:889-902. Uys GM, Ramburan A, Loos B, Kinnear CJ, Korkie LJ, Mouton J, Riedemann J, Moolman-Smook J. Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein C. BMC Cell Biol 12: 18, 2011. Valdivia HH, Kaplan JH, Ellis-Davies GC, Lederer WJ (1995) Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation. Science 267:1997-2000. Vargas MA, Tirnauer JS, Glidden N, Kapiloff MS, Dodge-Kafka KL, “Myocyte enhancer factor 2 (MEF2) tethering to muscle selective A-kinase anchoring protein (mAKAP) is necessary for myogenic differentiation,” Cell Signal. 2012 Aug;24(8):1496-503. Virshup DM (2000) Protein phosphatase 2A: a panoply of enzymes. Curr Opin Cell Biol 12:180- 185. Wang X, Tang X, Li M, Marshall J, Mao Z (2005) Regulation of neuroprotective activity of myocyte-enhancer factor 2 by cAMP-protein kinase A signaling pathway in neuronal survival. J Biol Chem 280:16705-16713. Wang, Y., E. G. Cameron, J. Li, T. L. Stiles, M. D. Kritzer, R. Lodhavia, J. Hertz, T. Nguyen, M. S. Kapiloff and J. L. Goldberg (2015). “Muscle A-Kinase Anchoring Protein-alpha is an Injury-Specific Signaling Scaffold Required for Neurotrophic- and Cyclic Adenosine Monophosphate-Mediated Survival.” EBioMedicine 2(12): 1880-1887. Wang, Z., H. I. Ma, J. Li, L. Sun, J. Zhang and X. Xiao (2003). “Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.” Gene Ther 10(26): 2105-2111. Wera S, Hemmings BA (1995) Serine / threonine protein phosphatases. Biochem J 311 ( Pt 1):17- 29. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD (2002) Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect m calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol 22:7603-7613. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD (2004) Calcineurin / NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118. Wong W, Goehring AS, Kapiloff MS, Langeberg LK, Scott JD, “mAKAP compartmentalizes oxygen-dependent control of HIF-1alpha,” Sci Signal. 2008 Dec 23;1(51). Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context- dependent regulation of anchored enzymes. Mol Interv 10: 86 -97, 2010. 114. Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH, Neel BG, Araki T. MEK-ERK pathway modulation ameliorates disease phe- notypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest. 2011;121:1009-1025. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, Chien KR. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130 / leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996;271:9535-9545. Writing Group, M., D. Mozaffarian, E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. R. Das, S. de Ferranti, J. P. Despres, H. J. Fullerton, V. J. Howard, M. D. Huffman, C. R. Isasi, M. C. Jimenez, S. E. Judd, B. M. Kissela, J. H. Lichtman, L. D. Lisabeth, S. Liu, R. H. Mackey, D. J. Magid, D. K. McGuire, E. R. Mohler, 3rd, C. S. Moy, P. Muntner, M. E. Mussolino, K. Nasir, R. W. Neumar, G. Nichol, L. Palaniappan, D. K. Pandey, M. J. Reeves, C. J. Rodriguez, W. Rosamond, P. D. Sorlie, J. Stein, A. Towfighi, T. N. Turan, S. S. Virani, D. Woo, R. W. Yeh, M. B. Turner, C. American Heart Association Statistics and S. Stroke Statistics (2016). “Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.” Circulation 133(4): e38-360. Wu H, Rothermel B, Kanatous S, Rosenberg P, Naya FJ, Shelton JM, Hutcheson KA, DiMaio JM, Olson EN, Bassel-Duby R, Williams RS (2001) Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 20:6414-6423. Xie M, Hill JA (2013) HDAC-dependent ventricular remodeling. Trends Cardiovasc Med 23:229-235. Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res. 2009;105:304-311. Yang J, Drazba JA, Ferguson DG, Bond M (1998) A-kinase anchoring protein 100 (AKAPlOO) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol 142:511-522. Yang KC, Jay PY, McMullen JR, Nerbonne JM. Enhanced car- diac PI3Ka signalling mitigates arrhythmogenic electrical remodel- ling in pathological hypertrophy and heart failure. Cardiovasc Res. 2012;93:252-262. Zakhary DR, Fink MA, Ruehr ML, Bond M (2000) Selectivity and regulation of A-kinase anchoring proteins in the heart. The role of autophosphorylation of the type II regulatory subunit of cAMP-dependent protein kinase. J Biol Chem 275:41389-41395. Zhang L, Malik S, Kelley GG, Kapiloff MS, Smrcka AV, “Phospholipase Cepsilon scaffolds to muscle-specific A kinase anchoring protein (mAKAPbeta) and integrates multiple hypertrophic stimuli in cardiac myocytes,” J Biol Chem. 2011 Jul 1;286(26):23012-21. Zhang, L., S. Malik, J. Pang, H. Wang, K. M. Park, D. I. Yule, B. C. Blaxall and A. V. Smrcka (2013). “Phospholipase Cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy.” Cell 153(1): 216-227. Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT, Wheeler MA, Ellis JA, Skepper JN, Vorgerd M, Schlotter-Weigel B, Weissberg PL, Roberts RG, Wehnert M, Shanahan CM (2007) Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet 16:2816-2833. Zhao Y, Bjorbaek C, Moller DE. Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. J Biol Chem. 1996;271:29773-29779. Zhao Y, Bjorbaek C, Weremowicz S, Morton CC, Moller DE. RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation. Mol Cell Biol. 1995 Aug; 15(8): 4353-436.

Claims

1. A nucleic acid encoding a molecule consisting of amino acids 2132 to 2319 of human muscle A-kinase anchor protein (mAKAP), The molecule inhibits the anchoring of protein (serine-threonine) phosphatase 2A (PP2A) to mAKAP and inhibits the dephosphorylation activity of PP2A to maintain the phosphorylation level of serum response factor (SRF), thereby providing a composition for treating heart failure or cardiovascular disease.

2. The composition of claim 1 , wherein the nucleic acid is contained in a vector.

3. The composition of claim 2 , wherein the vector is an adeno-associated virus (AAV).

4. The composition of claim 1, wherein the SRF comprises phosphorylation of Ser 103.

5. The composition described in claim 1, wherein the molecule has the sequence of SEQ ID NO:

9.

6. The composition described in claim 1, wherein the heart failure is heart failure with reduced ejection fraction.

7. The composition described in claim 1, wherein the composition inhibits phosphorylation of B56δ (PPP2R5D) of PP2A.

Images